

Transcriptional kinetic synergy: a complex landscape revealed by integrating modelling and synthetic biology

Rosa Martinez-Corral^{1,8}, Minhee Park^{2,3,4,8}, Kelly Biette^{1,5,8}, Dhana Friedrich¹, Clarissa Scholes^{1,6}, Ahmad S. Khalil^{2,3,7}, Jeremy Gunawardena¹, Angela H. DePace¹

1 Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.

2 Biological Design Center, Boston University, Boston, MA 02215, USA.

3 Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.

4 Present address: Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

5 Present address: Mercy BioAnalytics, Natick, MA 01760, USA.

6 Present address: Mammoth Biosciences, San Francisco, CA 94080, USA.

7 Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.

8 These authors contributed equally

ORCID IDs:

RMC: 0000-0003-3600-3601, MP: 0000-0002-2101-5485; DF: 0000-0003-2144-9280;

CS: 0000-0001-9208-3234; ASK: 0000-0002-8214-0546; JG:0000-0002-7280-1152;

AHD: 0000-0001-5723-0438

¹ 1 Summary

² Gene regulation involves synergistic interactions between transcription factors (TFs). Classical
³ thermodynamic models offer a biophysical understanding of synergy based on binding cooperativity
⁴ and regulated recruitment of RNA polymerase. However, transcription requires polymerase to
⁵ transition through multiple states. Accordingly, recent work has suggested that "kinetic synergy"
⁶ can arise through TFs differentially regulating distinct steps of the transcription cycle. Disentangling
⁷ both sources of synergy has been challenging. Here, we combine theory and experiment to
⁸ analyze TFs binding to a single shared site, thereby removing simultaneous specific DNA binding.
⁹ Using the graph-based linear framework, we integrate TF binding with regulation of the transcrip-
¹⁰ tion cycle, and reveal a complex kinetic synergy landscape dependent on TF concentration, DNA
¹¹ binding and transcriptional activity. We exploit synthetic zinc-finger TF fusions to experimen-
¹² tally interrogate these predictions. Our results confirm that transcription cycle regulation must be
¹³ integrated with recruitment for a quantitative understanding of transcriptional control.

¹⁴ 2 Keywords

¹⁵ gene regulation; synergy; transcription cycle; synthetic biology; mathematical modelling; linear
¹⁶ framework.

¹⁷ 3 Introduction

¹⁸ The regulation of transcription is a finely controlled process central to biology, biomedicine and
¹⁹ bioengineering applications. At its core are transcription factors (TFs), proteins that bind spe-
²⁰ cific sites on the DNA and directly or indirectly modulate the binding and activity of the RNA
²¹ polymerase complex. In eukaryotes, multiple TFs, of the same and distinct types, collaborate
²² to drive transcription through binding to gene regulatory regions called enhancers and promoters

23 (Field and Adelman, 2020). Such "combinatorial control" enables binding and response specificity
24 (Wunderlich and Mirny, 2009; Georges et al., 2010), and expands the regulatory capabilities of
25 the finite set of TFs encoded by an organism. A wealth of studies have characterised TF bind-
26 ing sites and binding profiles in model genes, genomes and random sequences (e.g. Smith et al.,
27 2013; Vandel et al., 2019; Inukai et al., 2017). In turn, a long-standing goal of biomedicine and
28 synthetic biology has been to exploit this type of information to anticipate the effect of mutations
29 on cell regulation, to develop new and more refined pharmacological interventions, and to design
30 next-generation synthetic circuits with more precise and robust functions. However, this is still a
31 difficult task, in part because of the non-independent effects of the TFs that control a given gene
32 (Ouyang et al., 2009; de Boer et al., 2020; Reiter et al., 2017; King et al., 2020; Nie et al., 2020).

33 When TFs interact to regulate transcription, the response to a combination of TFs is often not
34 simply predicted by the responses to each of the TFs alone. Some models indicate that in the
35 absence of interactions between TFs or sites, their combined effect should just be the addition of the
36 individual outputs, and "synergy" has been used to refer to deviation from this additive expectation
37 (Carey et al., 1990; Herschlag and Johnson, 1993; Scholes et al., 2017). Under other models,
38 "synergy" is manifested as multiplicativity in the response (Bintu et al., 2005a). Alternatively,
39 the term "synergy" has been used to refer to nonlinear response to increasing TF concentrations
40 (Carey, 1998), binding cooperativity (below), or a special form of it (Veitia, 2003; Michida et al.,
41 2020). Here we use the term "synergy" to refer to an increase in the expression output under two
42 TFs in comparison to their individual effects, quantified by a functional, model-agnostic measure
43 proposed in the Results section.

44 Synergy has commonly been understood through the lens of recruitment models of transcription,
45 where the role of TFs is to regulate the binding of the RNA polymerase to the gene (Ptashne,
46 2005). Thermodynamic models of gene regulation offer a biophysical grounding for this view
47 (Ackers et al., 1982; Bintu et al., 2005b,a). These models assume that TFs and polymerase bind to
48 the DNA under thermodynamic equilibrium conditions. The free energy of each state determines
49 its steady-state probability according to the Boltzmann distribution, and the transcription rate is
50 treated as a function of the states of binding of the system. Synergy then emerges from direct or
51 indirect cooperative binding interactions, where TFs enhance or reduce each other's binding and
52 that of the RNA polymerase to the DNA (e.g. Vashee et al., 1998; Ambrosetti et al., 2000; Spitz and
53 Furlong, 2012; Frank et al., 2012; Goldstein et al., 2017; Estrada et al., 2016). Mechanistically, this
54 can result from direct protein-protein interactions between adjacently-bound molecules, indirect
55 interactions through a shared molecule or complex like Mediator (Carey et al., 1990; Malik and
56 Roeder, 2010; Bashor et al., 2019) or through allosteric mechanisms (Biddle et al., 2021) mediated
57 by nucleosomes (Mirny, 2010) or by DNA (Narasimhan et al., 2015).

58 Beyond recruitment of RNA polymerase to the gene, it is well known that eukaryotic transcription
59 is a multi-step process that is tightly regulated at many points. Accordingly, it has been suggested
60 that transcriptional regulation should be understood in terms of a transcription cycle (Fuda et al.,
61 2009), involving for example the displacement of nucleosomes at the start site, post-translational
62 modification of histones (Mao et al., 2010; Hansen and O'Shea, 2013; Cui et al., 2020), assembly of
63 the transcriptional machinery, and post-translational modifications that regulate its activity and
64 elongation rate (Jonkers and Lis, 2015; Core and Adelman, 2019). In agreement with this view,
65 RNA polymerase has been found to be already bound on many inactive genes, suggesting that under
66 certain scenarios activation does not rely on regulating polymerase recruitment, but modulating a
67 subsequent step (Oven et al., 2007). Besides moving the focus away from the recruitment of the
68 RNA polymerase, this view also implies non-equilibrium behaviour, given that ATP-dependent
69 nucleosome remodelling and post-translational modifications involve energy dissipation. In this
70 case, the steady-state behaviour of the system is determined by the individual rates of the various
71 transitions. This is in contrast to the equilibrium situation of thermodynamic models, where only
72 the ratios between the forward and backward rates matter for determining the steady-state of the
73 system (Wong and Gunawardena, 2020).

74 Under this kinetic view, the possibility of "kinetic synergy" was theoretically proposed. Imagine the
75 simplest case where transcription is regulated by two steps, and two TFs have different biochemical
76 functions such that one TF can preferentially enhance one step and the other TF can preferentially

77 enhance the other. Then, when the two TFs are present together they can enhance each other's
78 effect and thus generate synergy (Herschlag and Johnson, 1993; Scholes et al., 2017). Importantly,
79 this would enable synergy to emerge even in the absence of cooperative binding between TFs on
80 the DNA; the TFs would not even need to be simultaneously present at the regulatory site.

81 Multiple lines of evidence make kinetic synergy very plausible. First, experimental work has shown
82 that transcriptional activators can increase gene expression by different mechanisms. Blau et al.
83 (1996) found that TF activation domains can either stimulate transcription initiation, elongation,
84 or both, and more recent studies have continued to reveal that TFs use diverse mechanisms to
85 regulate transcription and affect distinct steps of the transcription cycle (e.g. Fu et al., 2004; Rahl
86 et al., 2010; Baluapuri et al., 2019). Along the same lines, Danko et al. (2013) reported differences
87 in RNA polymerase II pausing depending upon treatment with E2 or TNF-alpha signals, which
88 were attributed to the TFs downstream (ER α and NF- κ B) acting on different transitions that
89 regulate their target genes. Moreover, comparisons between regulation driven by homogeneous or
90 heterogeneous sets of TFs have shown that heterogeneous sets often drive higher expression levels
91 (Smith et al., 2013; Vanhille et al., 2015; Singh et al., 2021). In line with this, Keung et al. (2014)
92 found evidence of synergistic activation between the viral activator VP16 and selected chromatin
93 regulators in a reporter system. Similarly, the activity of many *Drosophila* TFs and cofactors
94 was found to be highly context-dependent (Stampfel et al., 2015), suggesting that activation may
95 require a particular combination of biochemical mechanisms.

96 Despite these observations, it is experimentally challenging to assess kinetic synergy given the
97 difficulty of disentangling it from cooperative DNA-binding interactions between TFs. On the
98 theoretical side, there has been a lack of tools to reason about kinetic synergy on biophysical
99 grounds. As a first step, a recent theoretical study by our group showed that in a similar way
100 to binding cooperativity, kinetic synergy can implement logical and analog computations (Scholes
101 et al., 2017), and that it can generate a wide diversity of input/output relationships. However,
102 in a similar way to other modelling work that considers transcription as a multi-step process (e.g.
103 Suter et al., 2011; Hansen and O'Shea, 2013; Rybakova et al., 2015), that model did not explicitly
104 account for TF binding, and instead represented it indirectly through the effect of the TFs on the
105 transition rates of the system. To our knowledge, there have been few attempts to explicitly model
106 the interplay between TF binding, polymerase recruitment, and progression over the transcription
107 cycle. Li et al. (2018) proposed a model that explicitly incorporated binding and transitions over
108 the cycle, but assumed a time-scale separation between TF binding and the rest of the processes,
109 with quasi-equilibrium in TF binding. However, both TF residence times and the half-life of certain
110 biochemical steps in the transcription cycle may occur on similar timescales, on the order of several
111 seconds or a few minutes (Methods, section 6.2), calling for more general models that bring together
112 the binding-centered view of recruitment models with the regulation of the transcription cycle.

113 Here we exploit the graph-based linear framework (below) to propose a model of transcriptional
114 control that explicitly accounts for TF binding and the regulation of polymerase recruitment,
115 as well as the progression over the transcription cycle. In order to disentangle kinetic synergy
116 from binding cooperativity, we focus on the emergence of synergy between TFs binding to a
117 single, shared site. This scenario eliminates the possibility of TFs simultaneously bound to the
118 DNA, thus removing cooperative binding between TFs. Experimentally, we build this system
119 using engineered TFs where activation domains of a set of functionally diverse mammalian TFs
120 are fused to a computationally designed zinc-finger (ZF) DNA binding domain predicted to bind
121 only to an artificial site upstream of a reporter (Figure 1A) (Khalil et al., 2012; Keung et al.,
122 2014; Park et al., 2019b; Israni et al., 2021). We propose a comprehensive measure of synergy
123 where we compare the expression output when both TFs are present, to that when only one of
124 them is present. By exploring the synergistic behaviour of the model in parameter space, we find
125 that a diversity of behaviors can emerge in this setup, for which we find experimental evidence.
126 Our model reveals a complex synergy landscape, shaped by the interplay between the activation
127 effect of the TFs and their binding kinetics. This highlights the relevance of considering genomic
128 context, binding and biochemical function together when characterizing TFs, and illuminates how
129 functional interactions between TFs may contribute to eukaryotic transcriptional control.




Figure 1: A model for kinetic synergy between two TFs sharing a site. A) Cartoon schematizing the strategy of this work to examine kinetic synergy: two synthetic TFs regulate a reporter (not shown) through a shared binding site. As an example, TF A controls the first step in the transcription cycle, and TF B controls the second step. B) Model used in this work. The graph product of a binding graph \mathcal{N} , and a 3-state polymerase cycle graph \mathcal{P} , gives rise to the complete linear framework graph of the system ($\mathcal{N} \times \mathcal{P}$). Only a subset of nodes and edges are labelled, for clarity. The horizontal edges from the central cycle to the outer cycles denote binding of each of the TFs, and the reverse edges denote unbinding. The three cycles allow us to account for the effect of the TFs, since the rates can be different depending upon the state of the binding site. As an example, the darker arrows denote the activator effect of A and B on the first and second transitions, respectively ($k_{1,A} > k_{1,\emptyset}$, $k_{2,B} > k_{2,\emptyset}$). C) Schema of the full graph, as used in Figure 2.

130 4 Results

131 4.1 Mathematical model

132 We study how kinetic synergy emerges in a scenario where two TFs bind to a shared site in a
 133 regulatory sequence, such that only one TF can be specifically bound at any given time. Figure 1A
 134 schematizes this situation for a general 3-state transcription cycle, where TF A promotes the first

135 step (illustrated as the assembly of the RNA polymerase complex), and TF *B* promotes a process
136 downstream.

137 In order to model this system, we exploit the linear framework formalism, a graph-based approach
138 to Markov Processes that can be used to model a diversity of biological processes in a biophysically
139 realistic and mathematically tractable way (Gunawardena, 2012; Ahsendorf et al., 2014). We
140 have previously applied this framework to study how binding interactions between TFs modulate
141 gene expression by implicitly averaging over the states of the polymerase cycle (Estrada et al.,
142 2016; Biddle et al., 2019; Park et al., 2019a). In contrast, in a previous study of kinetic synergy,
143 we modelled the effect of TFs on a detailed transcription cycle but effectively combined their
144 binding with their enzymatic effects (Scholes et al., 2017). Here we propose a model that unifies
145 both approaches and doesn't make assumptions about the binding reactions being on a different
146 timescale than the polymerase cycle reactions, improving previous approaches in the literature (Li
147 et al., 2018) (Methods, 6.1).

148 The system is represented by a graph (Figure 1B, $\mathcal{N} \times \mathcal{P}$), whose vertices are the biological
149 states of interest, and the edges are the transitions between them, assumed to follow Markovian
150 dynamics with infinitesimal transition rates corresponding to the graph edge labels. Structurally
151 (i.e. ignoring edge labels) the graph for the complete system is the graph product between two
152 simpler graphs: a binding graph and a polymerase cycle graph. The binding graph for our sys-
153 tem of interest is represented in Figure 1B (Binding graph (\mathcal{N})), and consists of a binding site
154 that can either be empty, bound by TF *A*, or bound by TF *B*. For the polymerase cycle (Fig-
155 ure 1B, Polymerase cycle graph (\mathcal{P})), we consider the simplest cycle, with 3 states (labelled 1,2,3).
156 The first transition is assumed to be reversible, and the other two irreversible in agreement with
157 the macroscopic irreversibility of posttranslational modifications like phosphorylation, or the syn-
158 thesis of mRNA. mRNA is assumed to be produced when the system transitions from state 3 to
159 state 1. This simple graph can be interpreted in terms of empty transcription start site (TSS),
160 assembled RNA polymerase, and C-terminal phosphorylated or elongating polymerase, although
161 mapping onto specific states isn't required to interpret the results. Given these two graphs, tak-
162 ing all pairwise combinations of their vertices (graph product) gives the complete graph $\mathcal{N} \times \mathcal{P}$
163 (Figure 1B).

164 TF binding on-rates ($k_{b,X}$, $X \in \{A, B\}$, horizontal from the central cycle to the right and left) have
165 dimensions of (concentration \times time) $^{-1}$, and binding off rates ($k_{u,X}$, $X \in \{A, B\}$) have dimensions
166 of (time) $^{-1}$. The genomic context is modeled by the values of the basal rates over the polymerase
167 cycle in the absence of TFs (central cycle). To incorporate the effect of a TF on a given transition,
168 we assume that the TF only has effect while it is bound. The effect is then incorporated into the
169 edge label (parameter value) for that transition, making it different for the cycle where the TF is
170 bound than for the basal cycle. As an example, the darker arrows on the left and right cycles in
171 Figure 1B, $\mathcal{N} \times \mathcal{P}$, represent the activating effect of *A* and *B* on the first and second transitions,
172 respectively. In this case, $k_{1,A} > k_{1,\emptyset}$, and $k_{2,B} > k_{2,\emptyset}$. Similarly, repression could be included as
173 well by a smaller value for a transition rate than the corresponding basal rate. For simplicity here
174 we examine synergy between "pure" activators only, defined by not decreasing the clockwise rates
175 ($k_{1,X} \geq k_{1,\emptyset}$, $k_{2,X} \geq k_{2,\emptyset}$, $k_{3,X} \geq k_{3,\emptyset}$, $X \in \{A, B\}$) and not increasing the counterclockwise rate
176 ($k_{4,A} \leq k_{4,\emptyset}$, $k_{4,B} \leq k_{4,\emptyset}$).

177 We interpret the system in probabilistic terms, and assume each vertex of the graph holds the
178 probability of the system being in that state. The transition rates then determine the time-
179 evolution of the probabilities according to the Master Equation, which eventually reach a steady
180 state (Methods, 6.1). Moreover, we assume first-order mRNA degradation. By taking the mRNA
181 degradation rate as a constant that normalises the transition rates, the steady-state mRNA at a
182 given concentration of *A* and *B* ($m(A, B)^*$) is given by:

$$183 m(A, B)^* = k_{3,\emptyset} P_{3,\emptyset}^*(A, B) + k_{3,A} P_{3,A}^*(A, B) + k_{3,B} P_{3,B}^*(A, B) \quad (1)$$

184 where $P_{3,\emptyset}^*(A, B)$, $P_{3,A}^*(A, B)$, $P_{3,B}^*(A, B)$ are the steady-state probabilities of state 3_\emptyset , 3_A , 3_B at
185 concentrations *A* and *B* of the TFs, and the rates are normalised by the mRNA degradation rate
186 (Methods, 6.1). Given that we only consider the steady-state behaviour of the system, we use the
187 same symbols to refer to the original rates and the normalised rates in order to avoid excessive
188 notation. In the remainder of the paper, the rates will always be normalised.

189 The focus of the analysis is to compare this quantity when both TFs are present to that when
190 only one is present and the other is at concentration 0 (synergy, below). Note that when only one
191 or none of the TFs is present, m^* can be computed in the same way. In that case, the steady-
192 state probabilities for those states corresponding to the absent TF being bound will be 0, and
193 the rest will be redistributed according to the parameter values. The value of m^* in the absence
194 of TFs ($m^*(0, 0)$) corresponds to basal expression. For simplicity, the absence of a TF from the
195 mathematical expressions below means it is at concentration 0.

196 4.2 A measure of synergy

197 Our interest is to understand how synergy emerges in this system. As shown by Scholes et al. (2017),
198 if two TFs act on more than one step in the cycle, the overall effect may not be greater than additive
199 even if they interact kinetically. This exemplifies that considering addition as a null expectation
200 against which to define synergy, as has often been done in the literature, is model-specific. In order
201 to provide a model-agnostic definition of synergy, here we consider a two-dimensional quantity that
202 compares the steady-state expression when both TFs are present ($m^*(A, B)$) to the steady-state
203 expression when either of them is alone, but at twice as much concentration ($m^*(2A)$, $m^*(2B)$). In
204 this way, the total concentration of TF is the same in the combined as in the individual situation.
205 Enhanced expression in combination with respect to the strongest TF (the TF with a higher level
206 of expression on its own), or reduced with respect to the weakest, must arise as a result of the
207 functional interactions of the TFs over the cycle.

208 Positive synergy corresponds to higher expression in combination as compared to individually,
209 and can be regarded as "canonical" synergy in the sense of enhanced expression in combination:
210 expression is greater than that of the strongest TF even if half the molecules are substituted
211 by those of a weaker TF. We note however that the output does not have to be greater than
212 additive to be considered positive synergy. Negative synergy corresponds to lower expression in
213 combination, with expression lower than that of the weakest TF alone. Asymmetric synergy results
214 when expression is increased only with respect to the weakest TF. In this case, it may be unclear
215 whether there are any synergistic interactions. Potentially, these can still be detected depending on
216 the extent to which the expression is reduced or increased with respect to the strongest or weakest
217 TF, respectively. Thus, we propose to quantify synergy as a point in 2D, by comparing the effects
218 of adding one TF to the other. This is quantified by $S_{A,B}$ (effect of B on A) and $S_{B,A}$ (the effect
219 of A on B) as follows:

$$220 S_{A,B} = \log_2 \left(\frac{m^*(A, B)}{m^*(2A)} \right) \quad (2)$$

$$221 S_{B,A} = \log_2 \left(\frac{m^*(A, B)}{m^*(2B)} \right) \quad (3)$$

222 If A is taken to be the strongest TF, positive (green), asymmetric (blue) and negative (red) synergy
223 map to 3 quadrants of a two-dimensional synergy space, as depicted in Figure 2A.

224 4.3 Positive, negative or asymmetric synergy can theoretically emerge 225 from two activators

226 We begin by exploring the theoretically possible synergistic behaviours between two activators
227 ($k_{1,X} \geq k_{1,\emptyset}$, $k_{2,X} \geq k_{2,\emptyset}$, $k_{3,X} \geq k_{3,\emptyset}$, $k_{4,X} \leq k_{4,\emptyset}$, $X \in \{A, B\}$). In line with our experimen-
228 tal system where TFs are comprised of the same binding domain (below), we assume that both
229 TFs have the same binding kinetics (given by a binding rate k_b and an unbinding rate k_u) but
230 different activation capabilities (given by the $k_{i,X}$, $i \in \{1, 2, 3, 4\}$, $X \in \{A, B\}$). We assume the
231 concentration unit is incorporated in the binding on-rates, such that both A and B are present at
232 a concentration of 1 arbitrary unit each when they are both present together, and at concentration
233 2 when they are alone. In order to define the boundaries of the synergy space region that can
234 be covered by the model under biologically-plausible parameter values and constraints (Methods,
235 6.2), we numerically sampled the parameter space using a biased sampling algorithm (Methods,
236 6.3). We explored the synergy space when TFs act on the same step, exclusively complementary
237 steps, or all steps (Figure 2B).




Figure 2: Positive, negative or asymmetric synergy emerge in the model depending upon parameter values. A) Synergy space. See text for details. B) Regions of the synergy space spanned by 3 regulatory strategies. Top: A and B act on the first step exclusively. Middle: A on one of the first two steps, B on the other one. Bottom: A and B act on any step (to various degrees). Constraints for the boundary search (Methods, 6.2, 6.3): parameter values between 1 and 10^4 , TF rates at most 1000 times larger than the basal rates for the clockwise (k_1, k_2, k_3) or 0.001 times smaller for k_4 . Fold change in m^* for each TF individually (at concentration 2) with respect to the basal condition with no TF between 1 and 10. Figure S1B shows the results for more constrained parameters. (continued on next page)

Figure 2 (previous page): C) Distribution of TF activity distances per synergy quadrant for a random sample of parameter sets under the same constraints as in the bottom panel in B (synergies are plotted as a scatterplot in Figure S1C). D) The two most prevalent dominant flux paths for the points used in the analysis in C. The arrow diagrams represent the model states and transitions, as schematized in Figure 1C; arrow greyscale intensity denotes the average probability net flux for that transition over all the parameter sets that share the dominant path highlighted in magenta. Note that reversible edges may appear in both directions if some parameter sets have net flux in one direction and others in the other. The distributions underneath show contours for the two-dimensional histogram of synergy values corresponding to those parameter sets that share the same dominant path. See also Figure S2.

238 As a control, we first explored the case where both TFs enhance the first step. Figure 2B-top
239 shows that as expected, only asymmetric synergy appears in this case. Intuitively, if TF *A* drives
240 stronger expression than TF *B* but both act on the same step, then mixing *A* with *B* can only
241 reduce expression with respect to the strongest one, and increase it with respect to the weakest.

242 Next, we explored the case where TFs have complementary activities, with each TF enhancing
243 either the first or second transition. Figure 2B-middle shows that this control strategy mostly
244 results in positive synergy, but also covers a region of the asymmetric synergy quadrant (notice
245 that the result is restricted to the upper diagonal region of the positive quadrant due to the
246 definition of TF *A* as the strongest of the pair). A very similar result is obtained for any other pair
247 of complementary rates (Figure S1A). The appearance of asymmetric synergy in this case shows
248 that even if TFs have complementary activities, that may not be enough to enhance expression
249 beyond that of the strongest TF when half of its concentration is substituted by the weaker TF.

250 TFs are often found to interact with a wide range of cofactors and regulators (Dingar et al., 2015;
251 Kim et al., 2017; Carnesecchi et al., 2020), and it is therefore likely that they modulate multiple
252 processes albeit with different strengths. Hence, we next considered a more general scenario where
253 each TF can enhance any of the transitions to different extents (Figure 2B, bottom). In this case, a
254 slightly higher region of the positive and asymmetric synergy quadrants are occupied, and slightly
255 negative synergy can also emerge. We interpret this as an indication that under some parameter
256 values, TFs can interfere with each other's action and reduce the expression as compared to when
257 only one of them is present.

258 For all these cases, the synergy space region that can be spanned by the model becomes smaller
259 for more constrained parameter values, representing the assumption that the system has a smaller
260 basal expression and TFs are weaker (Figure S1B).

261 4.4 The activity of the TFs over the cycle is not the only determinant 262 of synergy

263 The original proposition of kinetic synergy stemmed from the assumption that synergy would
264 emerge from TFs acting on different rate-limiting steps in transcription (Herschlag and Johnson,
265 1993). In the case of TFs with potentially overlapping effects, to what extent is positive synergy
266 linked to TFs working exclusively, or nearly exclusively, on separate steps, so that they complement
267 each other to enhance the cycle? In order to address this question, we looked at the correspondence
268 between parameter values and synergy. For this, we generated a random sample of points that span
269 a wide region of the synergy space (plotted in Figure S1C, Methods, 6.4). In order to quantify the
270 degree of complementarity between the pair of TFs in a given parameter set, we use the following
271 measure, which we call TF activity distance: the sum, over all the polymerase cycle transitions,
272 of the absolute differences between the logarithms of the transition rates associated to each TF
273 (Figure 2C). Similar TF parameter values result in a small distance value, whereas TFs with big
274 differences in their rates, and therefore more divergent in their functions, result in a larger distance.
275 As shown in Figure 2C, positive synergy tends to emerge at higher distances than asymmetric and
276 negative synergies, suggesting more divergent functions is indeed linked to higher complementarity
277 and thus higher positive synergy.

278 However, the distances that lead to asymmetric synergy and those that lead to positive synergy
279 overlap, suggesting that the different functions of the TFs are not the only determinants of synergy
280 output. When binning the distributions by the basal expression (steady state m^* in the absence
281 of TFs) and binding and unbinding rates, these factors appear to be important as well: higher
282 basal expression and higher binding and unbinding rates correlate with less distant TFs producing
283 positive synergy (Figure S1D). In addition, the basal expression and binding rates also modulate
284 the correlation between the distance of two TFs and the extent of positive synergy that they exhibit
285 (Figure S1E).

286 Intuitively, for positive synergy to emerge, we would expect that each of the TFs binds and unbinds
287 appropriately as to be able to exert its effect and not interfere with the binding and the effect of
288 the other TF. In order to test the extent to which this is indeed linked to synergy, we looked at
289 the steady-state probability fluxes in the graph. Given the irreversible nature of the transitions of
290 the polymerase cycle, a net probability flux remains even when the system is at steady state. The
291 flux of probability of the system is intimately linked to the production of mRNA, since mRNA is
292 produced as the system transitions through the polymerase cycle. Formally, the flux from node i
293 to node j , $J_{i,j}$ is given by $J_{i,j} = k_{i,j} P_i$, with $k_{i,j}$ the transition rate between i and j , and P_i the
294 probability of node i . In the case of irreversible edges, this equals the net flux. In the case of
295 reversible edges, the net flux $\overline{J_{i,j}}$ can be defined as $\overline{J_{i,j}} = J_{i,j} - J_{j,i}$, with $J_{i,j} > J_{j,i}$.

296 For the same sample of points (parameter sets) as in Figure 2C, we computed the net fluxes in
297 the presence of A and B . Then, for each point, by starting at the polymerase-empty state with
298 no TF bound (state $1, \emptyset$ in Fig 1B, $\mathcal{N} \times \mathcal{P}$) we followed the transition with a higher net flux, and
299 repeated the same iteratively until reaching state $1, \emptyset$ again or any other node already encountered.
300 This generates what we call the dominant path of net fluxes over the graph. After computing the
301 dominant path for each of the parameter sets, we quantified how many parameter sets share the
302 same dominant path. For this analysis, we pulled together those pairs of paths that are mirror
303 images of each other, since they are equivalent.

304 Out of all the parameter sets sampled, the majority correspond to one of either two paths, repre-
305 sented in Figure 2D. The most predominant involves the binding of one TF, transition over the
306 first step (binding of polymerase), unbinding of the TF, and reversion to the empty state. The
307 two-dimensional density plot below the flux diagram shows that the majority of the points with
308 this dominant path of fluxes correspond to asymmetric synergy. In contrast, the second most fre-
309 quent dominant path involves cycling over the whole graph, with the first two transitions occurring
310 under one TF, and the last occurring under the other. In this case, the majority of the points
311 are associated with positive synergy. The rest of the dominant paths that make up to 90% of
312 all the dominant paths in the sample of points are shown in Figure S2. The density plots show
313 that dominant paths are not uniquely associated to individual synergy classes, but there are clear
314 biases, with positive synergy being mostly associated to dominant paths that traverse the whole
315 graph, and asymmetric synergy linked to dominant paths that show nonproductive cycling. This
316 agrees with the expectation that positive synergy should emerge when TFs act productively to
317 enhance progression over the polymerase cycle, but also suggests that an intricate balance between
318 all the transitions in the system is required for positive synergy to emerge.

319 4.5 Experimental evidence of kinetic synergy using a synthetic platform

320 The modelling results in the previous sections suggest that kinetic synergy can be observed from this
321 single binding site circuit. In order to experimentally test this idea, we developed a reporter system
322 in which synthetic TF fusions are recruited to a single binding site integrated into a mammalian
323 HEK293 cell line (Methods, 6.6,6.8) (Khalil et al., 2012; Park et al., 2019b; Israni et al., 2021).
324 We selected five activation domains of mammalian TFs with a described diversity of functions in
325 the literature. SP1 is a ubiquitous mammalian transcription factor whose mechanism of action
326 has classically been linked to the recruitment of the transcriptional machinery (O'Connor et al.,
327 2016). cMyc is also a ubiquitous regulator. It interacts with a diverse range of proteins, but
328 its mechanism of action has been predominantly linked to processes downstream the recruitment
329 of the transcriptional machinery, including pause-release (Rahl et al., 2010) and elongation via
330 interaction with the elongation factor Spt5 (Baluapuri et al., 2019). BRD4 has also been described

331 to have elongating activity, through the interaction with positive transcription elongation factor
 332 b (pTEF-b) (Yang et al., 2005; Moon et al., 2005). In addition, it has been involved in phase-
 333 separation at super-enhancers (Vasile et al., 2018), suggesting that BRD4 may also regulate other
 334 steps in the transcription cycle. Finally we chose the activation domain of HSF1, which has been
 335 described to have both initiating and pause-release stimulating activity, and a mutant version of
 336 it, which we call HSF1-m. This mutant was described to be elongation-deficient (Brown et al.,
 337 1998). Accordingly, these TFs can be broadly classified into either initiating (if they influence the
 338 recruitment of RNA polymerase) or elongating factors (if they influence a process downstream),
 as depicted in Figure 3A.




Figure 3: Experimental observation of kinetic synergy between 2 transcriptional activators on a synthetic platform. A) Schema of the synthetic TFs. B) Expression upon transfection with either 10 (1X) or 20 (2X) ng of one TF, or the ZF binding domain alone (grey). Error bars denote the 95% confidence interval for the mean GFP fold change, obtained from bootstrapping the mean GFP fold change values from all the experiments (biological replicates) for each condition. At least 3 biological replicates per condition, with 2-4 technical replicates each. C) Experimental synergy between two activators, defined as in Eqs. 2-3 (\log_2 of the ratio of average fold-change expression when 10 ng of each TF is transfected, over the average fold-change expression when 20 ng of one is transfected). TF A is the strongest of the pair in the single TF expression, as shown in the 2X conditions of panel B. Error bars denote ranges from at least three biological replicates, with 2-4 technical replicates each. Barplots corresponding to this data are shown in Figure S3F, and the synergy between each TF and the empty ZF is shown in Figure S3E.

339
 340 We engineered synthetic TFs (synTFs) composed of an activation domain from the above-described
 341 TFs fused to a synthetic zinc finger (ZF) DNA binding domain (Methods, 6.6), designed to target
 342 a 20-bp binding site that does not natively exist in the mammalian genome sequence (Figure 1A,
 343 Figure 3A) (Khalil et al., 2012; Park et al., 2019b; Israni et al., 2021). This allows us to specif-
 344 ically recruit the activation domains to a reporter to assess their effects on transcription, while
 345 minimizing confounding effects from native TFs acting on the reporter. We then stably integrated
 346 into HEK293FT cells a reporter, composed of a single target binding site upstream of a minimal
 347 CMV (minCMV) promoter driving the expression of a destabilized EGFP (d2EGFP) (Methods,
 348 6.8). Given its rapid turnover (Li et al., 1998), destabilized EGFP serves as a convenient genomic
 349 reporter of the mRNA expression level (Raj et al., 2006). The expression of the synTFs was in-

350 duced by transient transfection of the synTFs, whose expression level can be controlled by the
351 amount of the plasmids transfected (Figure S3A). We chose to transfet synTFs at either 10 or 20
352 ng to ensure that the concentration (i.e. expression level) of synTF is the limiting factor. Reporter
353 expression outcome was assessed by quantifying GFP fluorescence using flow cytometry 48 hours
354 later (Methods, 6.9, 6.10).

355 Figure 3B shows reporter activation by each of the synTFs. We observed similar activation
356 strengths varying from about 1.5 fold change in GFP fluorescence to 4 fold change, with slight in-
357 creases upon doubling the amount of TF transfected for most TFs. Such fold change up-regulation
358 is in the range of physiological induction in mammalian signalling pathways (Strasen et al., 2018;
359 Wong et al., 2019; Friedrich et al., 2019). A similar dose-dependent increase in reporter signal is
360 also observed at the mRNA level (Figure S3B), supporting the use of GFP fluorescence to report
361 on mRNA.

362 In order to assess the extent of synergy between pairs of TFs, we compared the fold-change in
363 GFP fluorescence when TFs were transfected in pairs at 10 ng each, to that when only one is
364 transfected at 20 ng. We used quantitative immunofluorescence targeting the HA-tag of the synTFs
365 to verify that transient transfection of 20 ng of coding plasmids for a single synTF results in a
366 similar synTF abundance distribution as when transfecting two TFs in combination at 10 ng each,
367 despite some variability inherent to the transfection procedure (Figure S3C,D) (Methods, 6.13).
368 Under these conditions, Figure 3C shows that both positive and asymmetric synergy appears (See
369 Figure S3F for details). Consistent with the correlation in the model between TF activity distance
370 and synergy class, the pairs exhibiting positive synergy (Fig 3C, green quadrant) correspond to
371 those where each TF predominantly has been described to have either initiating or elongating
372 factor activities. No TF was capable of increasing the expression from that driven by HSF1, which
373 is the strongest synTF in the set and is described to have both initiating and elongating activities
374 (Brown et al., 1998). However, different TFs reduced its expression to different extents, suggesting
375 some functional interactions are occurring (e.g. compare the $S_{A,B}$ coordinate for SP1-HSF1 and
376 cMyc-HSF1 in Figure 3C). For the pairs of TFs described to predominantly act upon the same
377 step, almost no synergy was detected (SP1-HSF1m, cMyc-BRD4).

378 Figure 3B shows a very modest activation effect from the ZF alone (no TF activation domain) case.
379 However, the combination with a full synTF only leads to asymmetric synergy (Figure S3E), with
380 all TFs except HSF1 being reduced by the same extent, and HSF1 being reduced even further.
381 This suggests that although the ZF may have a small effect perhaps by increasing the ability of
382 the basal transcriptional machinery to bind, the positive synergy observed between pairs of TFs
383 is most likely due to their activation domains, since the ZF only reduces expression when mixed
384 with any of the TFs.

385 These results show that positive synergy can emerge experimentally even when the TFs share
386 the same binding site. However, the effects are small. One potential reason is that the TFs are
387 weak, in agreement with the model (Figure S1B). Moreover, the distributions of Figure S1D-E
388 and the analysis of the dominant flux paths in Figure 2 point to binding and unbinding kinetics
389 as important contributors to synergy as well. We now focus on this point.

390 4.6 Kinetic synergy depends upon the binding and unbinding kinetics

391 We explored how the synergy exhibited by a pair of TFs changes in the model as a function of
392 either the unbinding or the binding rate. We began by examining the effect of the unbinding rate.
393 To this end, we randomly sampled parameter sets for the basal rates over the polymerase cycle
394 ($k_{1,\emptyset}, k_{2,\emptyset}, k_{3,\emptyset}, k_{4,\emptyset}$) and binding and unbinding (k_b, k_u). For each of these basal sets, we sampled
395 parameter values for pairs of TFs ($k_{1,A}, k_{2,A}, k_{3,A}, k_{4,A}, k_{1,B}, k_{2,B}, k_{3,B}, k_{4,B}$). For each pair,
396 we varied the unbinding rate k_u over a 2 order magnitude range, 10 fold up and down the basal
397 value, and tracked the corresponding behavior over the synergy space. Given that the unbinding
398 rate changes expression from each TF alone, we only considered those parameter sets where the
399 strongest TF is the same across the unbinding rates considered, so that synergy is consistently
400 defined throughout. Further details of this procedure are given in Methods, 6.5.

401 To classify the behavior over the synergy space systematically, we considered that the binding and




Figure 4: Synergy between a pair of TFs depends upon the binding and unbinding kinetics. (continued on next page)

Figure 4 (previous page): A) Model examples for 5 sets of parameter values demonstrating the diversity in how synergy changes as a function of the unbinding rate. For each example, the top-left plot shows the fold change in expression as compared to no TF present, for each of the TFs at concentration 2 (black, gray), or both TFs at concentration 1 (maroon), as a function of the unbinding rate. The top-right plot shows the corresponding behavior in synergy space. The circles on the bottom of the top-left plot and those on the top-right plot correspond to the same values of synergy. Marker size is related to binding affinity (smallest marker: smallest affinity, highest unbinding rate). Shown below are the diagrams depicting the net fluxes (grey colormap) and dominant flux path (magenta) for the two extreme k_u values. All examples share the same basal parameter values: $k_{1,\emptyset} = 4.288$, $k_{2,\emptyset} = 11.023$, $k_{3,\emptyset} = 3.414$, $k_{4,\emptyset} = 10.362$. $k_b = 180.19$. TF associated parameter values are as follows: pnnd : $k_{1,A} = 120.985$, $k_{2,A} = 154.358$, $k_{3,A} = 4.561$, $k_{4,A} = 2.854$, $k_{1,B} = 5.007$, $k_{2,B} = 25.685$, $k_{3,B} = 15.086$, $k_{4,B} = 2.083$; pnndi : $k_{1,A} = 6.317$, $k_{2,A} = 517.659$, $k_{3,A} = 1433.877$, $k_{4,A} = 1.095$, $k_{1,B} = 11.275$, $k_{2,B} = 326.127$, $k_{3,B} = 15.328$, $k_{4,B} = 10.223$; npii : $k_{1,A} = 4.844$, $k_{2,A} = 6345.641$, $k_{3,A} = 151.500$, $k_{4,A} = 7.354$, $k_{1,B} = 4.504$, $k_{2,B} = 17.664$, $k_{3,B} = 2601.429$, $k_{4,B} = 3.088$; npid : $k_{1,A} = 6.784$, $k_{2,A} = 740.850$, $k_{3,A} = 56.436$, $k_{4,A} = 2.010$, $k_{1,B} = 4.821$, $k_{2,B} = 11.997$, $k_{3,B} = 909.506$, $k_{4,B} = 8.354$; ppii : $k_{1,A} = 937.265$, $k_{2,A} = 8084.904$, $k_{3,A} = 5.392$, $k_{4,A} = 1.982$, $k_{1,B} = 9.945$, $k_{2,B} = 18.372$, $k_{3,B} = 2047.513$, $k_{4,B} = 8.447$; See also Figure S4. B) Quantification of the change in dominant path in the presence of both TFs, from the smallest to the largest $S_{A,B}$. The parameter values were obtained from a rejection based sampling algorithm, as explained in section 6.5. The number of parameter sets analysed for each class are as follows: npii: 13103 parameter sets, corresponding to 214 basal parameter sets. npid: 4461, corresponding to 264 basal parameter sets. pnnd: 2833, corresponding to 87 basal parameter sets. pnndi: 2215, corresponding to 132 basal parameter sets. C) Region of the synergy space spanned by the model under parameter constraints determining weak basal expression and weak TFs: basal expression parameter values between 1-100 for clockwise rates, 100-1000 for $k_{4,\emptyset}$. TF parameter values at most 100X greater (0.01X smaller for k_4). Fold change from each TF alone at 2X concentration limited to 5. k_b and k_u are either same for both TFs (dotted line), or different (solid line). For the case of same binding, it is the same result as the dotted line in Figure S1B, right.

402 unbinding rate are related to affinity by $K_a = k_b[TF]/k_u$, and we used the relationship between
403 changes in synergy and affinity so that the same criteria can be used to analyse the results when
404 perturbing either the binding or the unbinding rate. We focused on the positive and asymmetric
405 synergy behaviors, and used a 4-bit string that captures the behaviour at the affinity extremes:
406 the first position denotes if $S_{A,B}$ is positive (p) or negative (n) at highest affinity, and the second
407 position denotes the sign at the lowest affinity. The third and fourth positions denote whether
408 $S_{A,B}$ and $S_{B,A}$ increase (i) or decrease (d), respectively. We disregard those situations where there
409 is no change. As a result, there are theoretically 12 possible behaviors. We found that for some
410 basal sets of parameters, changing the unbinding rate could result in all 12 possible behaviors,
411 depending on the pair of TF parameter values. One such example is shown in Figure S4A, and
412 selected examples are shown in Figure 4A. Similar results were found when modulating the binding
413 on-rate k_b (Figure S4B), which can be interpreted as modulating the baseline concentration of the
414 TFs at 1X concentration.

415 As expected from typical occupancy-based hypotheses, we found instances where increasing affinity
416 led to an increase in synergy (Figure 4A, more affinity-more synergy), changing from asymmetric
417 to positive. In contrast, we also found examples where even if the expression from the individual
418 and combined TFs decreases with less affinity, synergy increases and can change from asymmetric
419 to positive as affinity is reduced (Figure 4A, less affinity-more synergy). As seen in Figure S4 and
420 depicted at the bottom of Figure 4A, we found many instances of nonmonotonic behaviour, where
421 synergy was maximal at intermediate affinities.

422 To examine the relationship between the change in synergy class and the cycling over the system
423 promoted by the TFs, we determined the dominant paths of net fluxes at steady state for parameter
424 sets where synergy changes between asymmetric and positive or vice-versa as a function of the
425 unbinding rate. We calculated the dominant path for the lowest and highest $S_{A,B}$ in the presence

426 of both TFs. For each dominant path, we assessed whether it spanned nodes in each of the three
427 binding configurations of the system ("full path") or not ("restricted path"), as depicted for the
428 corresponding examples of Figure 4A. Then, for each parameter set, we assessed whether the
429 path type changed between the smallest and largest $S_{A,B}$ value, and plotted the quantification
430 in Figure 4B. As expected, and in line with the examples in Figure 4A, the barplot shows that
431 in the majority of the cases, the change from smallest to highest $S_{A,B}$ value correlates with a
432 transition from a restricted to a full dominant path. For the case where increasing the unbinding
433 rate causes synergy to increase only with respect to TF A (npid), we found many instances with
434 no change of path class, and a small set where the relationship was reversed. This result aligns
435 well with those of the previous sections, which show that the synergy of a pair of TFs ultimately
436 depends on the overall system behaviour and the intricate balance between all the transitions.
437 However, a major contributor to the synergistic behaviour of the TFs is the productive cycling
438 over the system, with each TF binding and unbinding appropriately to allow the other to exert its
439 effect. Therefore, we hypothesized that by combining pairs with different activation domains and
440 affinities, synergy might be further enhanced. In agreement with this, the synergy space covered
441 by the model expands slightly when weak TFs have different binding and unbinding rates, as
442 compared to when their binding parameters are the same as we have considered in the previous
443 analyses (Figure 4C). This suggests a scenario where the combinatorial effect of TFs can be flexibly
444 tuned by the combined effect of their biochemical activities and binding.

445 5 Discussion

446 In eukaryotic transcription, combinatorial control occurs at multiple scales, with many TFs binding
447 to a given enhancer, and many enhancers controlling the activity of a gene (Spitz and Furlong,
448 2012). Here we have focused on the first scale, and have investigated how synergy between TFs
449 can emerge as a result of the kinetics of the system. Though kinetic synergy was theoretically
450 proposed almost 30 years ago (Herschlag and Johnson, 1993), its experimental demonstration has
451 been challenging, largely due to the confound of cooperative binding interactions. To circumvent
452 this limitation, we have focused on a scenario where only one TF can be specifically bound at
453 any given time. By forcing the TFs to act separately in time, their functional interactions can be
454 revealed. In order to reason about this scenario, we have proposed a minimal biophysical model
455 that explicitly accounts for the kinetics of the binding as well as the functional effects of the
456 transcription factors over the transcription cycle. The model reveals that synergy between a pair
457 of TFs is not an intrinsic feature of the pair, but depends upon the balance between their binding
458 and their functional effects. This work gives yet another example of the power of synthetic biology
459 to answer fundamental biological questions (Crocker et al., 2017; Park et al., 2019a; Bashor et al.,
460 2019).

461 A measure of synergy

462 In order to quantify synergy, it has been common to measure the deviation from additivity, under
463 the assumption that if TFs do not interact, then their combined effect should be the sum of the
464 effects obtained when each TF is present alone (Carey, 1998). Multiplicativity has also been taken
465 as a measure of synergy (Bintu et al., 2005a). However, in Scholes et al. (2017) we showed that
466 when TFs interact functionally on a 2-step cycle, additivity or multiplicativity is only expected
467 under very restricted circumstances. In order to provide a model-agnostic measure of synergy,
468 here we propose to compare expression when both TFs are present together, to expression when
469 only one of them is present, under the same total TF concentration. By having the same total
470 TF concentration in both cases, changes in the expression when there are two TFs as compared to
471 only one must be due to their functional interactions, and therefore provides evidence of synergy.
472 In addition to positive synergy, we define asymmetric and negative synergy. This enables the
473 quantitative characterization of the synergy between a pair of TFs as a function of a variable of
474 the system, by looking at the corresponding trajectory in synergy space. Although this measure
475 is particularly suited for the single binding site scenario explored here, we suggest it could also be
476 used to quantitatively characterize the response to combinations of TFs in a more natural scenario
477 where each TF binds to distinct sites.

478 **A model that explicitly accounts for the interplay between TF binding and polymerase
479 activity**

480 In order to reason about the single binding site experiment, we have developed a model with details
481 of both the binding of the TFs and the progression over the polymerase cycle. This model brings
482 together the two main modelling frameworks of transcription in the literature, where either the
483 binding is taken implicitly (e.g. Scholes et al., 2017), or the polymerase cycle is not detailed (e.g.
484 Estrada et al., 2016). In contrast to other attempts in the literature (Li et al., 2018), we don't
485 make assumptions about the timescales of the binding and unbinding of the TFs with respect to
486 those of the biochemical transitions over the polymerase cycle. This provides greater generality.
487 In addition, the model can easily be extended to include more polymerase states and more binding
488 sites for other TFs or coregulators, if such details become relevant in future studies. One of the
489 simplifying assumptions of the model is that TFs only exert their effect while they are bound. We
490 note that this doesn't necessarily have to be the case, since they may act through other cofactors
491 that can remain bound even if the TF unbinds. This could be easily incorporated at the expense of
492 more states and parameters. However, we think it wouldn't fundamentally change our conclusions,
493 since there would also be an interplay between the binding kinetics of these other components and
494 the kinetic effects on the cycle.

495 We have explored the behavior of the model in parameter space under the assumption that the
496 system is at steady state. This is a widely used assumption and reasonable for our experimental
497 setup, given the time between transfection and measurement of mRNA levels. However, one of the
498 contexts where combinatorial control is most relevant is development, and many developmental
499 processes may be too fast to allow for a steady state to be reached. In this case, it may become
500 important to explicitly incorporate the time delay that emerges from polymerase travelling along
501 the gene body, which we have not accounted for. Although at steady state this is likely to be
502 effectively incorporated by the parameter of the last transition rate in the polymerase cycle, it
503 could have important implications when considering how synergy emerges in transient regimes,
504 and will be a relevant point to consider in future studies.

505 **Kinetic synergy can emerge when two TFs time-share a binding site**

506 We have found that extensive positive synergy is theoretically possible in the case where two ac-
507 tivators bind to the same site on DNA. Our analysis shows that this is due to TFs productively
508 enhancing the polymerase cycle when acting in combination, by binding and unbinding appropri-
509 ately to allow each TF to exert its effect. We note that the extent of positive synergy experimentally
510 observed is small compared to the regions covered by the model. In the model, we have found
511 that the region of the synergy space is reduced as more constraints on the parameters are imposed,
512 especially when constraining the extent to which a TF can enhance a given rate, and the expression
513 fold change that it causes. Therefore, the small synergy experimentally observed suggests that the
514 synTFs have relatively weak effects, in agreement with the small fold-change activation that they
515 produce.

516 According to the model, synergy between a pair of TFs is strongly influenced by their binding
517 kinetics. Theoretically, both the binding on-rate and off-rate can modulate the synergy exhibited
518 by a pair of TFs, and lower affinity can increase the synergy observed for a pair of TFs, even
519 if this reduces expression from the TFs acting individually. In some cases, the compromise is
520 evidenced as a nonmonotonic effect of affinity upon synergy. ZFs with different binding affinities
521 can be obtained by introducing mutations in the ZF scaffold that are known to mediate non-
522 specific interactions with DNA (Khalil et al., 2012). In future work, synTF variants can be used to
523 systematically explore the role of binding affinity on synergy. Given the small effects of individual
524 synTFs on transcription, which may be weakened further by affinity mutations, it will be critical
525 to have fine control over synTF expression, and dynamic measurements in single cells are likely to
526 be informative.

527 Our previous analyses had suggested that assessing synergy might be a way to elucidate the
528 mechanism of action of TFs (Scholes et al., 2017). However, the current analysis shows that this
529 is confounded by the effect of the binding kinetics. Moreover, parameter constraints that generate
530 positive synergy in the model also generate asymmetric synergy. In this case, even if TFs may have

531 complementary activities, their binding patterns may be imbalanced and may not allow productive
532 interaction. In the case where either of the TFs works exclusively on one of two complementary
533 steps, this contrasts with the finding of exclusively greater-than-additive behaviour by Scholes et al.
534 (2017), highlighting the importance to account for the binding kinetics.

535 The model also shows that when TFs have overlapping activities, negative synergy can emerge
536 even if individually they act to enhance the cycle. Again, this arises due to an imbalance between
537 the timescales of their binding and functional effects, where in combination they interfere with
538 each other. However, the extent of this effect is small and requires very fine tuned parameter sets,
539 as evidenced by the low numbers of points in this region obtained from pure random sampling. In
540 agreement with this, we did not robustly observe negative synergy experimentally.

541 Implications for gene regulation in natural scenarios

542 In endogenous enhancers, some TFs do have overlapping binding sites as in our setup (Han et al.,
543 1998; Pan and Nussinov, 2011; Cheng et al., 2013). However, most typically, each TF has its
544 own binding site. Even in this case, binding kinetics may still be important. The residence time
545 of the TF on the DNA must be long enough for it to be able to exert its function. However, it is
546 plausible that there could be interference either directly or through recruited cofactors, such
547 that output may be maximized at intermediate affinities. This could be another reason behind
548 the widespread presence of relatively low-affinity binding sites in eukaryotes (Ramos and Barolo,
549 2013; Farley et al., 2016; Crocker et al., 2016; Kribelbauer et al., 2019), and the observation of
550 fast TF binding kinetics (Paakinaho et al., 2017; Li et al., 2019; Donovan et al., 2019). Moreover,
551 tuning binding site affinity might be an effective way to modulate expression beyond fully adding
552 or removing a binding site, which could have evolutionary implications (Kurafeiski et al., 2019).
553 Along the same lines, kinetic synergy relaxes the need for strict arrangements between binding
554 sites, another typical feature of eukaryotic transcriptional control (Kulkarni and Arnosti, 2003;
555 Junion et al., 2012; Smith et al., 2013).

556 TF activity has often been considered to be modular. In this view, the activity of the activation
557 domain is independent of that of the binding domain, which is assumed to be important only
558 to target the TF to specific sites on the genome (Ptashne, 1988). Evidence against this model
559 includes allosteric interactions between the DNA binding domain and the activation domain (Li
560 et al., 2017), and the observation that the activation domain may be involved in DNA recognition
561 (Brodsky et al., 2020). Adding to this, our work highlights the importance of considering TFs as
562 a unit, where the binding and activation domains together dictate the effect of the TF. Our study
563 emphasizes the value of considering an integrated view of transcriptional control, where the effect
564 of a TF has to be understood in terms of the other components of the system.

565 6 Methods

566 6.1 Modelling details and the linear framework

567 In this work we have used the linear framework formalism to model the interplay between the
568 TF binding and their effects on the transcription cycle. This framework was introduced in (Gu-
569 nawardena, 2012) and we have previously exploited it to study other problems in gene regulation.
570 Ahsendorf et al. (2014); Estrada et al. (2016); Biddle et al. (2019, 2021) can be consulted for
571 details. We outline the main features here.

572 A biological system is represented by a finite, directed, labelled graph G with labelled edges
573 and no self-loops. The graph represents a coarse-grained version of the system of interest, with
574 the nodes being the states of interest, and the edges the transitions between them. The edge
575 labels are the infinitesimal transition rates for the underlying Markov process, with dimensions
576 of $(\text{time})^{-1}$, and they include terms that specify the interactions between the graph and the
577 surrounding environment. For example, the transitions that represent the binding of a TF have
578 edge labels that include the TF concentration, which is assumed to remain constant over time
579 (i.e. TF is sufficiently in excess that, to a good approximation, binding does not reduce the
580 concentration of free TF available for binding).

581 The graph defines the time-evolution of the probability for each state of the system (vertex) as
 582 follows. Assume that each edge is a chemical reaction that follows mass-action kinetics with the
 583 edge label as the rate. Since each edge has only one source vertex, the resulting dynamics is linear
 584 and is described by a matrix equation,

$$585 \quad \frac{d\vec{P}}{dt} = \mathcal{L}(G)\vec{P}. \quad (4)$$

586 Here, \vec{P} is the column vector of state probabilities at time t , with dimension n , and $\mathcal{L}(G)$ is the
 587 Laplacian matrix of the graph. Eq. 4 is the master equation, or Kolmogorov forward equation, of
 588 the underlying Markov process.

589 For a strongly connected graph, the system has a unique steady state, where $d\vec{P}/dt = 0$. The
 590 steady-state probability values for each state are computed by summing over the products of the
 591 rate labels for each of the spanning trees rooted at that state, and normalising appropriately (see
 592 Estrada et al. (2016) for details).

593 The mRNA concentration m is assumed to evolve according to:

$$594 \quad \frac{dm}{dt} = k_{3,\emptyset}P_{3,\emptyset} + k_{3,A}P_{3,A} + k_{3,B}P_{3,B} - \delta_m m \quad (5)$$

595 where the $P_{3,X}$ are the probabilities of states 3_\emptyset , 3_A , 3_B at a given time (Figure 1B). By assuming
 596 steady state, setting $dm/dt = 0$, and dividing by δ_m , we obtain the expression for the steady state
 597 mRNA (* denotes steady state):

$$598 \quad m^* = \frac{k_{3,0}}{\delta_m} P_{3,\emptyset}^* + \frac{k_{3,A}}{\delta_m} P_{3,A}^* + \frac{k_{3,B}}{\delta_m} P_{3,B}^* \quad (6)$$

$$599 \quad m^* = \overline{k_{3,0}} P_{3,\emptyset}^* + \overline{k_{3,A}} P_{3,A}^* + \overline{k_{3,B}} P_{3,B}^* \quad (7)$$

600 This gives Eq. 1 of the main text, where the overbars are dropped for simplicity. In the parameter
 601 exploration, we directly sample on the normalised rates.

602 6.2 Biologically plausible ranges for parameter values

603 We considered a biologically plausible range for the normalised parameter values to be between 1
 604 and 10^4 , according to the following reasoning:

605 The events from the binding of the polymerase complex until the production of an mRNA molecule
 606 involve many biochemical reactions, including the binding interactions associated with the assembly
 607 of the pre-initiation complex, the phosphorylation of the C-terminal domain of RNA polymerase
 608 and other post-translational modifications (Schröder et al., 2013), as well as the biochemistry
 609 associated to elongation. Our 3-state cycle is therefore a coarse-grained representation of all
 610 these processes. In order to determine biologically plausible parameter ranges, we searched for
 611 measurements of reaction rates for these processes, and normalised those to typical rates of mRNA
 612 degradation, taken to have typical half-lives between 10 min (0.00116 s^{-1}) and 5 h (3.85×10^{-5}
 613 s^{-1}) (Sharova et al., 2009; Chan et al., 2018).

614 For a reaction at a rate of 0.7 s^{-1} ($\sim 1 \text{ s}$ half-life), normalizing by the mRNA degradation rates
 615 would result into a normalised range of 600-18000.

616 For a rate of 0.07 s^{-1} ($\sim 10 \text{ s}$ half-life), the normalised range would be 60-1800.

617 For a rate of 0.016 s^{-1} ($\sim 1 \text{ min}$ half-life), the normalised range would be 10-300.

618 And for a rate of 0.00116 s^{-1} ($\sim 10 \text{ min}$ half-life) the normalised range would be 1-30.

619 These values are consistent with measurements of various transcription-associated biochemical
 620 reactions: the *in vitro* rate of pre-initiation complex assembly was found to vary over ranges on

621 the order 10^{-3} s^{-1} (Ferguson et al., 2001) to 0.1 s^{-1} (Kugel and Goodrich, 1998), and the rate
622 of promoter opening/escape was reported to be 0.002 s^{-1} (Kugel and Goodrich, 1998). Pause
623 stability is estimated to be from 3 s to 20 min (Wissink et al., 2019). And the TF residence time
624 can be from just a few seconds to a few minutes (Paakinaho et al., 2017; Mehta et al., 2018).

625 Therefore, we took a range of $1\text{-}10^4$ for our parameter values. We note that we also checked the
626 results with smaller ranges, around slower rates for the polymerase cycle, but found that it didn't
627 affect the results qualitatively, only reduced the synergy region as shown in Figure S1B.

628 6.3 Synergy space boundary for a regulatory strategy

629 In order to determine the region of the synergy space that can be spanned by a given regulatory
630 strategy, we used a biased random sampling algorithm, modified from that in Estrada et al. (2016).
631 Parameters were chosen from a given range of normalised rate values, and TFs were assumed to
632 at most modify the basal rates by a certain factor (see figure captions for the values corresponding
633 to each figure). A maximum fold change for expression in the presence of one TF alone (at 2X
634 concentration) was also pre-specified, such that parameter sets that generate expression outside
635 this range were discarded. The steps of the algorithm are as follows:

- 636 1. Define constraints and two-dimensional grid of synergy values. Initialize with the hyperpa-
637 rameters (below).
- 638 2. Randomly sample parameter values from their range (in log scale) until 10 points are found
639 that fall in different cells of the grid.
- 640 3. Until convergence: at each iteration, search the surrounding parameter space of each bound-
641 ary point (see below) and keep the new parameter sets that generate synergy values not
642 already found (empty cells). Convergence is determined by 3000 iterations where no new
643 points occupying empty cells are found.

644 In order to search the surrounding parameter space of a given parameter set (point in synergy
645 space), we followed 3 strategies (each point was modified using the 3 strategies at each iteration,
646 provided there were sufficient points for steps 2 (10) and 3 (100)):

- 647 1. Randomly select a few parameter values and modify them.
- 648 2. "Pull" towards a target point in the direction determined by the centroid and the point being
649 modified, away from the boundary: for 500 trials or until convergence, slightly modify the
650 parameter set, and keep the new one if it generates a point in synergy space closer to the
651 target.
- 652 3. "Pull" in the direction (approximately) perpendicular to the tangent between the point being
653 modified and its neighbor, as in 2.

654 The algorithm depends on various hyperparameters: probability of selecting a parameter value
655 for mutation (0.2, 0.5), probability of replacing an already-existing boundary parameter (0.2, 0.6),
656 width of the interval around a parameter value to sample for new parameter values (in log (base
657 10) scale: [-2,2],[-1.5,1.5],[-1,1]). Searches were run for all 12 combinations of hyperparameters,
658 and results were merged together.

659 The boundary search code is available at <https://github.com/rosamc/GeneRegulatoryFunctions>.
660 The rest of the code to reproduce the calculations and figures in the paper is available at <https://github.com/rosamc/kinsyn-2021>.

662 6.4 Random sample of points in synergy space

663 In order to randomly sample parameter values in the synergy space we followed a rejection sam-
664 pling approach. Parameters were sampled logarithmically from its predefined range ($1\text{-}10^4$). The
665 constraints on the maximum fold change effect on the polymerase cycle rates by the TFs were
666 checked, as well as the constraint on the expression fold change by each of the TFs at 2X. We
667 collected 1 million parameter sets that satisfied the constraints. Then, in order to have a more
668 uniform distribution of points over the synergy space, we binned the synergy space into a grid with

669 bins every 0.025 $S_{A,B}$ and $S_{B,A}$, and kept one parameter set per bin. We repeated the procedure
670 10 times. The resulting points are those in Figure S1C.

671 6.5 Exploration of synergy as a function of binding or unbinding rate

672 In order to explore how synergy depends upon the binding and unbinding rates, we generated sets
673 of basal parameters by randomly sampling on a logarithmic scale the basal rates between 1 and 10^4 ,
674 and the binding and unbinding rates between $10^{1.5}$ and 10^3 . For each of these basal parameter
675 sets, we generated parameter sets corresponding to the TF-associated parameters, and we kept
676 1000 such parameter sets that satisfy the following constraints: i) TF-associated parameter values
677 at most 1000X the respective basal ones (0.001X for counterclockwise rate k_4); ii) fold change in
678 expression by each TF individually at 2X concentration between 1 and 5; iii) TF A is consistently
679 the strongest of the pair when the binding or unbinding rate is changed by a factor f , where f
680 spans 10 logarithmically spaced values between 0.1 and 10. For each parameter set that satisfied
681 the constraints, we determined the class of behaviour in synergy space as a function of the change
682 in the binding or unbinding rate over this two-order magnitude range, and saved for downstream
683 analysis those parameter sets where the absolute value of the change in both $S_{A,B}$ and $S_{B,A}$ was
684 at least 0.05.

685 6.6 Construct design and cloning

686 The reporter construct consists of a single synthetic zinc finger binding site (CGGCGTAGC-
687 CGATGTCGCGC) upstream of a minimal CMV promoter (taggcgtgtacgggtggaggccatataagca-
688 gagctcgtttagtgaaccgtcagatgcctgga) driving d2EGFP (EGFP destabilized with signal peptide for
689 fast degradation (fusion with aa 422-461 of mouse ornithine decarboxylase)).

690 synTF fusion proteins containing an activation domain of interest fused to an N-terminal zinc-finger
691 binding domain with a GGGGS flexible linker were driven under control of a ubiquitin promoter
692 and contain a 5' sv40 nuclear localization sequence, C-terminal HA and rabbit globin polyA 3'
693 UTR. Genome-orthogonal zinc fingers were previously developed to target 20-bp sequences that
694 minimize identity with the reference human genome (Israni et al., 2021; Park et al., 2019b). The
695 following protein domains were selected and conjugated as respective activation domains according
696 to previous studies:

697 SP1 (Residues 263 – 499) [PMID: 8278363]
698 NITLLPVNSVSAATLTPSSQAVTISSSGSQESGSQPVTSVTTISSASLVSSQASSSSFTNANSY
699 STTTTTSNMGIMNFTTSGSSGTNSQGQTPQRVSGLQGSDALNIQQNQTSGGSLQAGQQKE
700 GEQNQQTQQQQQILIPQQLVQGGQALQALQAAPLSGQTFTTQAISQETLQLNLQAVPNSGP
701 IIIRTPTVGPNGQVSWQLQLQVQNPQAQTITLAPMQGVSLGQTSSSN

702
703 cMyc (Residues 1-70) [PMID: 12177005]
704 MDFFRVVENVQQPPATMPLNVSFTNRNYLDYDSVQPYFY
705 CDEEEENFYQQQQQSELQPPAPSEDIWKKFEL

706
707 BRD4 (Residues 1308-1362) [PMID: 24860166]
708 PQAQSSQPQSMLDQQRELARKREQERRREAMAATIDMFQSDLLSIFEENLF

709
710 HSF1 (Residues 370-529) [PMID: 9606196]
711 PEKCLSVACLDKNELSDHLDAMDSNLDNLQTMSSHGFSVDTTSALLDLFSPSVTPDMSLP
712 DLDSSLASIQLLSPQEPPRPEAENSSPDGKQLVHYTAQPLFLLDPGSVDTGSNDLPVLF
713 ELGEGESYFSEGDGFAEDPTISLLTGSEPPKAKDPTVS

714
715 HSF1 mutant (Residues 370-529, F418A, F492A, F500A) [PMID: 9606196]
716 PEKCLSVACLDKNELSDHLDAMDSNLDNLQTMSSHGFSVDTTSALLDLASPSVTVPDMS
717 LPDLDSSLASIQLLSPQEPPRPEAENSSPDGKQLVHYTAQPLFLLDPGSVDTGSNDLP

719 VLAELGEGSYASEGDGFAEDPTISLLTGSEPPKAKDPTVS
720

721 6.7 Cell culture

722 HEK293FT cells (Thermo Fisher Scientific) were used as a background cell line in this study.
723 Cells were cultured in DMEM with L-glutamine, 4.5g/L Glucose and Sodium Pyruvate (Thermo
724 Fisher Scientific) supplemented with 10% FBS (Clontech), GlutaMAX supplement (Thermo Fisher
725 Scientific), MEM Non-Essential Amino Acids solution (Thermo Fisher Scientific) and 1% penicillin-
726 streptomycin (Thermo Fisher Scientific). Cells were maintained at 37°C with 5% CO₂ in a hu-
727 midified incubator, with splitting every 2-3 days.

728 6.8 Genomic integration of reporter constructs

729 Reporter lines were generated by site-specific integration of reporter constructs into HEK293FT
730 cells using CRISPR/Cas9 mediated homologous recombination into the AAVS1 (PPP1R2C) locus
731 as previously described (Park et al., 2019b). Briefly, 60,000 cells were plated in a 48-well plate
732 and transfected the following day by PEI with a mixture of the following: 70ng of gRNA_AAVS1-
733 T2 plasmid (Addgene 41820), 70 ng of VP12 humanSpCas9-Hf1 plasmid (Addgene 72247), and
734 175 ng of donor reporter plasmid. Donor reporter plasmids contain flanking arms homologous to
735 the AAVS1 locus, a puromycin resistance cassette, and constitutive mCherry expression. After
736 transfection, cells were cultured in 2 mg/mL puromycin selection for at least 2 weeks with splitting
737 1:10 every 3 days. Monoclonal populations for reporter cell lines were isolated by sorting single
738 cells from this population into a 96-well plate and growing cell lines from each well. A minimum
739 of 6 monoclonal cell lines that express high level of mCherry protein were transiently transfected
740 with a strong synTF activator (HSF1 or VP16) and a monoclonal cell line to be used going forward
741 was selected based on the fold-change of GFP expression relative to basal GFP level.

742 6.9 Transient transfection

743 Stable reporter cell lines were transfected with synTF plasmid constructs using polyethylenimine
744 (PEI, Polysciences) as described in (Park et al., 2019b). 60,000-100,000 cells/well were plated in
745 48-well plates and transfected the following day with a total of 10ng per synTF, unless otherwise
746 noted, with single stranded filler DNA (Thermo Fisher Scientific) up to 200ng total. 50ng of
747 pCAG-iRFP720 (Addgene, #89687) was used as a transfection control plasmid. Two days after
748 transfection, cells were collected and prepared for flow cytometry, unless otherwise noted.

749 6.10 Flow cytometry and data analysis

750 For each measurement, cells were harvested and run on an Attune NxT (Thermo Fisher Scientific)
751 or LSR II (BD) Flow Cytometer equipped with a high-throughput auto-sampler. A minimum of
752 10,000 events were collected for each well and were gated by forward and side scatter for live cells
753 and single cells, as described in (Park et al., 2019b). Cells were then gated by iRFP for transfection-
754 positive populations. The geometric mean of GFP fluorescence distribution was calculated in
755 FlowJo (Treestar Software). GFP expression fold-change was determined by normalizing with
756 mean GFP intensity of the reporter only control. Flow cytometer laser/filter configurations used
757 in this study were: EGFP (488 nm, 510/10), mCherry (561 nm, 615/25), iRFP-720 (638 nm,
758 720/30). All flow cytometry measurements were performed in technical replicates. Considering
759 together all replicates from all experiments with the same transfection condition, we checked for
760 consistency and discarded technical errors. This removed the cMyc 2X condition in one of the
761 experiments since it yielded an aberrantly low fold change. Moreover, we removed 4 additional
762 replicates, each from a different condition, that had a fold change that was above/below two
763 standard deviations from the mean considering all replicates for that condition together.

764 **6.11 Western blotting**

765 A reporter cell line was transfected with indicated amounts of ZF-HSF1 (0, 10, 20, 50, 100, 150,
766 200ng) in a 48-well plate at a cell density of 1x10⁵ per well. After 2 days, cells were rinsed with PBS
767 and lysed with 200 μ L of NuPAGE LDS sample buffer (Thermo Fisher Scientific), followed by 5
768 seconds of sonication. Whole cell lysates were mixed with NuPAGE Sample Reducing agent (10X,
769 Thermo Fisher Scientific) at 95°C for 5 minutes. Samples were then loaded into a 4-12% NuPAGE
770 Bis-Tris Mini Protein precast gel (Thermo Fisher Scientific) and were run at 200V for 30 minutes
771 in NuPAGE MES SDS Running Buffer. Separated proteins were transferred to a PVDF membrane
772 using P0 protocol of iBlot2 system (Thermo Fisher Scientific). Membranes were blocked for 1hr at
773 room temperature in blocking solution (5% w/v nonfat dry milk in 1X PBST) with gentle rocking.
774 The membranes were probed with anti-HA (1:4000; Abcam ab9110) and anti-GAPDH (1:1000;
775 Abcam ab9485) antibodies at room temperature for 1 hour with gentle rocking. The membranes
776 were washed in PBST three times for 5 minutes each, and incubated with a goat anti-rabbit IgG-
777 HRP antibody (1:2000; Abcam ab6721). The target proteins were visualized by chemiluminescence
778 using SuperSignal West Pico PLUS substrate (Thermo Fisher Scientific) and an iBright Western
779 Blot Imaging Systems (Thermo Fisher Scientific). Quantification of band intensities was carried
780 out using FIJI (Schindelin et al., 2012).

781 **6.12 Quantitative Real-Time PCR**

782 1×10^5 Hek293 reporter cells were seeded one day prior to transfection in 6cm culture dishes.
783 Transfection was performed with the indicated amounts of synTF plasmid as described above
784 for flow cytometry experiments using polyethylenimine (PEI) (polyscience) or Lipofectamine 3000
785 (Thermo Fisher Scientific). Two days post transfected, cell pellets were harvested and mRNA
786 was extracted using the RNeasy Mini Kit (Qiagen). 500 ng extracted total RNA was reverse
787 transcribed into cDNA for each sample. Reverse transcription was performed using Protoscript II
788 reverse transcriptase (New England Biolabs) and oligo-dT primers (New England Biolabs). Quantitative
789 real-time PCR was performed in triplicates using iTaqTM Universal SYBR[®] Green reagent
790 (Bio-Rad) on a CFX96 PCR machine (Bio-Rad). Primers were used in a final concentration of
791 243.2 nM. β -actin expression was used as a reference gene for relative quantification of RNA levels.
792 Used primer sequences are (5'-3'):

793 Actin_fwd: GGCACCCAGCACAATGAAGATCAA;
794 Actin_rev: TAGAACGATTGCGGTGGACGATG;
795 eGFP_fwd: AAGTTCATCTGCACCACCG;
796 eGFP_rev: TCCCTTGAAGAAGATGGTGCG;

797
798 **6.13 Comparison of synTF distribution across transfection conditions**
799 **using quantitative immunofluorescence**

800 **6.13.1 Immunostaining**

801 0.5×10^5 cells were seeded on poly-Lysine coated high-precision glass coverslips (18 mm round,
802 #1.5) in 12-well culture plates one day prior to transfection. Transfection was performed as
803 described for flow cytometry experiments. A total amount of 200 ng DNA (20 ng synTFs and
804 180 ng ssDNA) was used for transfection experiments. PEI was scaled to 12-well plate volume of
805 100 μ L total transfection mix. 48 h post transfection, cells were washed with 1x PBS, fixed with
806 2% PFA (Fisher Scientific) and blocked for 30 min with 10% Goat serum (VWR) in 1x PBS after
807 washing. Immunodetection was performed with HA-tag (6E2) mouse antibody (Cell Signaling)
808 1:1000 in 1%BSA/PBS overnight. Cell were washed with 0.1% Triton X-100 and incubated with
809 anti-mouse IgG Alexa Fluor 488 (#4408, Cell Signaling) antibody 1:1000 in 1%BSA/PBS for
810 1h. After washing with 0.1% Triton X-100, nuclei were stained with 2 μ g/mL Hoechst-33342
811 (Thermo Fisher Scientific) and mounted on glass slides using Prolong Gold Antifade (Thermo
812 Fisher Scientific). Image acquisition was performed at least 16 h after mounting slides.

813 **6.13.2 Fluorescence microscopy**

814 Images were acquired as single-plane multipoint positions on a Nikon Ti2 inverted microscope
815 upon illumination by a Lumencor Sola 395 Light Engine and a Plan Apo VC 20x objective (NA
816 0.75). The following filter sets were used. Alexa Fluor 488: excitation FF01-466/40, emission
817 FF03-525/50, dichroic FF495-Di03 (all Semrock); Hoechst-33342: excitation ET395/25x, emission
818 ET460/50m, dichroic ET425lp (all Chroma). Detection was performed with a Hamamatsu ORCA
819 Flash 4.0 LT camera. NIS elements software for image acquisition was used.

820 **6.13.3 Image Processing**

821 Images were extracted from nd2 files, separated as .tif-files per channel and field of view. CellPro-
822 filer 4.0 (McQuin et al., 2018) was used for image segmentation and measuring nuclear fluorescence
823 intensity. A pipeline was customized based on the pipeline for Human cells provided by the Cell-
824 Profiler project. Nuclei segmentation was performed based on Hoechst-33342 staining using Otsu
825 thresholding and a nuclear diameter range of 15 – 50 pixels. Objects outside that range and touch-
826 ing the border of images were excluded. Touching objects were distinguished based on fluorescence
827 intensity and object intensity was calculated for the segmented nuclear area in all channels.

828 **6.13.4 Data analysis**

829 The integrated fluorescence intensity (FI) calculated per nucleus for anti-HA-488 staining (detect-
830 ing HA-tagged synTF) was used for further data analysis using custom scripts in Matlab for data
831 processing. In case of multiple datasets of the same condition, FI distributions were joined. Back-
832 ground fluorescence was defined based on nuclear fluorescence intensity in untransfected controls.
833 Data was normalized to the 5th-95th percentile to remove outliers from imperfect segmentation
834 due to clumping of nuclei. The median was calculated and a threshold of 2.5 fold of the median was
835 determined to identify positive transfected cells (Figure S3C). Nuclei with FI above this threshold
836 were considered as positive transfected with any synTF condition described (Figure S3D). Dis-
837 tributions are plotted as probability density functions (PDF) using ksdensity function in Matlab.
838 The 5th-95th percentile of values above threshold for each condition was taken to remove outliers
839 for each condition to compare the distributions of synTF abundance in each dataset (Figure S3C).

840 **7 Acknowledgements**

841 We thank members of the DePace, Khalil and Gunawardena labs for helpful discussions. Fluores-
842 cence Microscopy experiments were performed at The Nikon Imaging Center at Harvard Medical
843 School. We thank Jennifer Waters and Rylie Walsh for guidance and support. This work was sup-
844 ported by NSF grant MCB-1713855 (A.S.K.)/ MCB-1715184 (A.H.D), NIH grant 1R01GM122928
845 (A.H.D. and J.G.), NIH grant R01EB029483 (A.S.K.), NSF CAREER IOS-1452557 (A.H.D.),
846 EMBO Fellowship 683-2019 (R.M.C.) and the Giovanni Armenise Harvard Foundation (A.H.D.).
847 A.S.K. also acknowledges funding from the NIH Director's New Innovator award (1DP2AI131083-
848 01), an NSF CAREER award (MCB-1350949), and a DARPA Young Faculty award (D16AP00142).
849 A.H.D. also gratefully acknowledges funding from the Lynch Foundation Systems Biology Fellow-
850 ship, the McKenzie Family Charitable Trust Systems Biology Fellowship Fund, and the John and
851 Virginia Kaneb Fellowship award at Harvard Medical School.

852 References

853 Ackers, G. K., Johnson, A. D., and Shea, M. A. (1982). Quantitative model for gene regulation
854 by lambda phage repressor. *Proceedings of the National Academy of Sciences*, 79(4):1129–1133.

855 Ahsendorf, T., Wong, F., Eils, R., and Gunawardena, J. (2014). A framework for modelling gene
856 regulation which accommodates non-equilibrium mechanisms. *BMC Biology*, 12(1):102.

857 Ambrosetti, D. C., Schöler, H. R., Dailey, L., and Basilico, C. (2000). Modulation of the activity
858 of multiple transcriptional activation domains by the DNA binding domains mediates the syner-
859 gistic action of Sox2 and Oct-3 on the Fibroblast growth factor-4 enhancer. *Journal of Biological
860 Chemistry*, 275(30):23387–23397.

861 Baluapuri, A., Hofstetter, J., Dudvarski Stankovic, N., Endres, T., Bhandare, P., Vos, S. M.,
862 Adhikari, B., Schwarz, J. D., Narain, A., Vogt, M., Wang, S. Y., Düster, R., Jung, L. A.,
863 Vanselow, J. T., Wiegering, A., Geyer, M., Maric, H. M., Gallant, P., Walz, S., Schlosser, A.,
864 Cramer, P., Eilers, M., and Wolf, E. (2019). MYC Recruits SPT5 to RNA Polymerase II to
865 Promote Processive Transcription Elongation. *Molecular Cell*, 74(4):674–687.e11.

866 Bashor, C. J., Patel, N., Choubey, S., Beyzavi, A., Kondev, J., Collins, J. J., and Khalil, A. S.
867 (2019). Complex signal processing in synthetic gene circuits using cooperative regulatory assem-
868 blies. *Science*, 364(6440):593–597.

869 Biddle, J. W., Martinez-Corral, R., Wong, F., and Gunawardena, J. (2021). Allosteric conforma-
870 tional ensembles have unlimited capacity for integrating information. *eLife*, 10:1–47.

871 Biddle, J. W., Nguyen, M., and Gunawardena, J. (2019). Negative reciprocity, not ordered assem-
872 bly, underlies the interaction of Sox2 and Oct4 on DNA. *eLife*, 8.

873 Bintu, L., Buchler, N. E., Garcia, H. G., Gerland, U., Hwa, T., Kondev, J., Kuhlman, T., and
874 Phillips, R. (2005a). Transcriptional regulation by the numbers: applications. *Current opinion
875 in genetics & development*, 15(2):125–35.

876 Bintu, L., Buchler, N. E., Garcia, H. G., Gerland, U., Hwa, T., Kondev, J., and Phillips, R.
877 (2005b). Transcriptional regulation by the numbers: models. *Current opinion in genetics &
878 development*, 15(2):116–24.

879 Blau, J., Xiao, H., McCracken, S., O'Hare, P., Greenblatt, J., and Bentley, D. (1996). Three func-
880 tional classes of transcriptional activation domain. *Molecular and Cellular Biology*, 16(5):2044–
881 2055.

882 Brodsky, S., Jana, T., Mittelman, K., Chapal, M., Kumar, D. K., Carmi, M., and Barkai, N.
883 (2020). Intrinsically Disordered Regions Direct Transcription Factor In Vivo Binding Specificity.
884 *Molecular Cell*, 79:1–13.

885 Brown, S. A., Weirich, C. S., Newton, E. M., and Kingston, R. E. (1998). Transcriptional activation
886 domains stimulate initiation and elongation at different times and via different residues. *EMBO
887 Journal*, 17(11):3146–3154.

888 Carey, M. (1998). The enhanceosome and transcriptional synergy. *Cell*, 92(1):5–8.

889 Carey, M., Lin, Y.-s., Green, M. R., and Ptashne, M. (1990). A mechanism for synergistic activation
890 of a mammalian gene by GAL4 derivatives. *Nature*, 345(May):361–364.

891 Carnesecchi, J., Sigismondo, G., Domsch, K., Baader, C. E. P., Rafiee, M. R., Krijgsveld, J., and
892 Lohmann, I. (2020). Multi-level and lineage-specific interactomes of the Hox transcription factor
893 Ubx contribute to its functional specificity. *Nature Communications*, 11(1).

894 Chan, L. Y., Mugler, C. F., Heinrich, S., Vallotton, P., and Weis, K. (2018). Non-invasive measure-
895 ment of mRNA decay reveals translation initiation as the major determinant of mRNA stability.
896 *eLife*, 7:1–32.

897 Cheng, Q., Kazemian, M., Pham, H., Blatti, C., Celniker, S. E., Wolfe, S. A., Brodsky, M. H., and
898 Sinha, S. (2013). Computational Identification of Diverse Mechanisms Underlying Transcription
899 Factor-DNA Occupancy. *PLoS Genetics*, 9(8).

900 Core, L. and Adelman, K. (2019). Promoter-proximal pausing of RNA polymerase II: a nexus of
901 gene regulation. *Genes & Development*, 33:1–23.

902 Crocker, J., Preger-Ben Noon, E., and Stern, D. L. (2016). *The Soft Touch: Low-Affinity Tran-*
903 *scription Factor Binding Sites in Development and Evolution*, volume 117. Elsevier Inc., 1
904 edition.

905 Crocker, J., Tsai, A., and Stern, D. L. (2017). A Fully Synthetic Transcriptional Platform for a
906 Multicellular Eukaryote. *Cell Reports*, 18(1):287–296.

907 Cui, G., Dong, Q., Duan, J., Zhang, C., Liu, X., and He, Q. (2020). NC2 complex is a key factor
908 for the activation of catalase-3 transcription by regulating H2A.Z deposition. *Nucleic Acids*
909 *Research*, pages 1–17.

910 Danko, C. G., Hah, N., Luo, X., Martins, A. L., Core, L., Lis, J. T., Siepel, A., and Kraus, W. L.
911 (2013). Signaling Pathways Differentially Affect RNA Polymerase II Initiation, Pausing, and
912 Elongation Rate in Cells. *Molecular Cell*, 50(2):212–222.

913 de Boer, C. G., Vaishnav, E. D., Sadeh, R., Abeyta, E. L., Friedman, N., and Regev, A. (2020). De-
914 ciphering eukaryotic gene-regulatory logic with 100 million random promoters. *Nature Biotech-*
915 *nology*, 38(1):56–65.

916 Dingar, D., Kalkat, M., Chan, P. K., Sri Kumar, T., Bailey, S. D., Tu, W. B., Coyaud, E., Ponzielli,
917 R., Kolyar, M., Jurisica, I., Huang, A., Lupien, M., Penn, L. Z., and Raught, B. (2015). BioID
918 identifies novel c-MYC interacting partners in cultured cells and xenograft tumors. *Journal of*
919 *Proteomics*, 118:95–111.

920 Donovan, B. T., Huynh, A., Ball, D. A., Patel, H. P., Poirier, M. G., Larson, D. R., Ferguson,
921 M. L., and Lenstra, T. L. (2019). Live-cell imaging reveals the interplay between transcription
922 factors, nucleosomes, and bursting. *The EMBO journal*, pages 1–18.

923 Estrada, J., Wong, F., DePace, A., and Gunawardena, J. (2016). Information Integration and
924 Energy Expenditure in Gene Regulation. *Cell*, 166(1):234–244.

925 Farley, E. K., Olson, K. M., Zhang, W., Rokhsar, D. S., and Levine, M. S. (2016). Syntax com-
926 pensates for poor binding sites to encode tissue specificity of developmental enhancers. *Proceedings*
927 *of the National Academy of Sciences of the United States of America*, 113(23):6508–6513.

928 Ferguson, H. A., Kugel, J. F., and Goodrich, J. A. (2001). Kinetic and mechanistic analysis of
929 the RNA polymerase II transcription reaction at the human interleukin-2 promoter. *Journal of*
930 *Molecular Biology*, 314(5):993–1006.

931 Field, A. and Adelman, K. (2020). Evaluating Enhancer Function and Transcription. *Annual*
932 *Review of Biochemistry*, 89(1):213–234.

933 Frank, T. D., Carmody, A. M., and Kholodenko, B. N. (2012). Versatility of cooperative tran-
934 *scriptional activation: A thermodynamical modeling analysis for greater-than-additive and less-*
935 *than-additive effects*. *PLoS ONE*, 7(4).

936 Friedrich, D., Friedel, L., Finzel, A., Herrmann, A., Preibisch, S., and Loewer, A. (2019). Stochas-
937 *tic transcription in the p53-mediated response to DNA damage is modulated by burst frequency*
938 *. Molecular Systems Biology*, 15(12):1–20.

939 Fu, D., Wen, Y., and Ma, J. (2004). The co-activator CREB-binding protein participates in
940 *enhancer-dependent activities of bicoid*. *Journal of Biological Chemistry*, 279(47):48725–48733.

941 Fuda, N. J., Ardehali, M. B., and Lis, J. T. (2009). Defining mechanisms that regulate RNA
942 *polymerase II transcription in vivo*. *Nature*, 461(7261):186–92.

943 Georges, A. B., Benayoun, B. A., Caburet, S., and Veitia, R. A. (2010). Generic binding sites,
944 generic DNA-binding domains: where does specific promoter recognition come from? *The
945 FASEB Journal*, 24(2):346–356.

946 Goldstein, I., Paakinaho, V., Baek, S., Sung, M.-H., and Hager, G. L. (2017). Synergistic gene
947 expression during the acute phase response is characterized by transcription factor assisted
948 loading. *Nature Communications*, 8(1):1849.

949 Gunawardena, J. (2012). A Linear Framework for Time-Scale Separation in Nonlinear Biochemical
950 Systems. *PLoS ONE*, 7(5):e36321.

951 Han, W., Yu, Y., Su, K., Kohanski, R. A., and Pick, L. (1998). A Binding Site for Multiple Tran-
952 scriptional Activators in the fushi tarazu Proximal Enhancer Is Essential for Gene Expression
953 In Vivo. *Molecular and Cellular Biology*, 18(6):3384–3394.

954 Hansen, A. S. and O’Shea, E. K. (2013). Promoter decoding of transcription factor dynamics
955 involves a trade-off between noise and control of gene expression. *Molecular systems biology*,
956 9(704):704.

957 Herschlag, D. and Johnson, F. B. (1993). Synergism in transcriptional activation: a kinetic view.
958 *Genes & Development*, 7(2):173–179.

959 Inukai, S., Kock, K. H., and Bulyk, M. L. (2017). Transcription factor-DNA binding: beyond
960 binding site motifs. *Current Opinion in Genetics and Development*, 43:110–119.

961 Israni, D. V., Li, H.-S., Gagnon, K. A., Sander, J. D., Roybal, K. T., Joung, J. K., Wong, W. W.,
962 and Khalil, A. S. (2021). Clinically-driven design of synthetic gene regulatory programs in human
963 cells. *bioRxiv*, page 2021.02.22.432371.

964 Jonkers, I. and Lis, J. T. (2015). Getting up to speed with transcription elongation by RNA
965 polymerase II. *Nature Reviews Molecular Cell Biology*, 16(3):167–177.

966 Junion, G., Spivakov, M., Girardot, C., Braun, M., Gustafson, E. H., Birney, E., and Furlong,
967 E. E. M. (2012). A transcription factor collective defines cardiac cell fate and reflects lineage
968 history. *Cell*, 148(3):473–486.

969 Keung, A. J., Bashor, C. J., Kiriakov, S., Collins, J. J., and Khalil, A. S. (2014). Using Targeted
970 Chromatin Regulators to Engineer Combinatorial and Spatial Transcriptional Regulation. *Cell*,
971 158(1):110–120.

972 Khalil, A. S., Lu, T. K., Bashor, C. J., Ramirez, C. L., Pyenson, N. C., Joung, J. K., and
973 Collins, J. J. (2012). A Synthetic Biology Framework for Programming Eukaryotic Transcription
974 Functions. *Cell*, 150(3):647–658.

975 Kim, B. R., Coyaud, E., Laurent, E. M., St-Germain, J., Van De Laar, E., Tsao, M. S., Raught,
976 B., and Moghal, N. (2017). Identification of the SOX2 interactome by BioID reveals EP300
977 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma
978 growth. *Molecular and Cellular Proteomics*, 16(10):1864–1888.

979 King, D. M., Hong, C. K. Y., Shepherdson, J. L., Granas, D. M., Maricque, B. B., and Cohen, B. A.
980 (2020). Synthetic and genomic regulatory elements reveal aspects of cis-regulatory grammar in
981 mouse embryonic stem cells. *eLife*, 9:1–24.

982 Kribelbauer, J. F., Rastogi, C., Bussemaker, H. J., and Mann, R. S. (2019). Low-Affinity Binding
983 Sites and the Transcription Factor Specificity Paradox in Eukaryotes. *Annual Review of Cell
984 and Developmental Biology*, 35(1):357–379.

985 Kugel, J. F. and Goodrich, J. A. (1998). Promoter escape limits the rate of RNA polymerase
986 II transcription and is enhanced by TFIIE, TFIIF, and ATP on negatively supercoiled DNA.
987 *Proceedings of the National Academy of Sciences of the United States of America*, 95(16):9232–
988 9237.

989 Kulkarni, M. M. and Arnosti, D. N. (2003). Information display by transcriptional enhancers.
990 *Development*, 130(26):6569–6575.

991 Kurafeiski, J. D., Pinto, P., and Bornberg-Bauer, E. (2019). Evolutionary potential of cis-regulatory
992 mutations to cause rapid changes in transcription factor binding. *Genome Biology and Evolution*,
993 11(2):406–414.

994 Li, C., Cesbron, F., Oehler, M., Brunner, M., and Höfer, T. (2018). Frequency Modulation of
995 Transcriptional Bursting Enables Sensitive and Rapid Gene Regulation. *Cell Systems*, 6(4):409–
996 423.e11.

997 Li, J., Dong, A., Saydaminova, K., Chang, H., Wang, G., Ochiai, H., Yamamoto, T., and Pertsinidis,
998 A. (2019). Single-Molecule Nanoscopy Elucidates RNA Polymerase II Transcription at Single
999 Genes in Live Cells. *Cell*, 178(2):491–506.e28.

1000 Li, J., White, J. T., Saavedra, H., Wrabl, J. O., Motlagh, H. N., Liu, K., Sowers, J., Schroer, T. A.,
1001 Thompson, E. B., and Hilsler, V. J. (2017). Genetically tunable frustration controls allostery in
1002 an intrinsically disordered transcription factor. *eLife*, 6:1–17.

1003 Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C. C., and Kain, S. R. (1998).
1004 Generation of destabilized green fluorescent protein as a transcription reporter. *Journal of
1005 Biological Chemistry*, 273(52):34970–34975.

1006 Malik, S. and Roeder, R. G. (2010). The metazoan Mediator co-activator complex as an integrative
1007 hub for transcriptional regulation. *Nature Reviews Genetics*, 11(11):761–772.

1008 Mao, C., Brown, C. R., Falkovskaia, E., Dong, S., Hrabeta-Robinson, E., Wenger, L., and Boeger,
1009 H. (2010). Quantitative analysis of the transcription control mechanism. *Molecular Systems
1010 Biology*, 6(431):1–12.

1011 McQuin, C., Goodman, A., Chernyshev, V., Kamentsky, L., Cimini, B. A., Karhohs, K. W., Doan,
1012 M., Ding, L., Rafelski, S. M., Thirstrup, D., Wiegraebe, W., Singh, S., Becker, T., Caicedo,
1013 J. C., and Carpenter, A. E. (2018). CellProfiler 3.0: Next-generation image processing for
1014 biology. *PLOS Biology*, 16(7):e2005970.

1015 Mehta, G. D., Ball, D. A., Eriksson, P. R., Chereji, R. V., Clark, D. J., McNally, J. G., and Karpova,
1016 T. S. (2018). Single-Molecule Analysis Reveals Linked Cycles of RSC Chromatin Remodeling
1017 and Ace1p Transcription Factor Binding in Yeast. *Molecular Cell*, 72(5):875–887.e9.

1018 Michida, H., Imoto, H., Shinohara, H., Yumoto, N., Seki, M., Umeda, M., Hayashi, T., Nikaido,
1019 I., Kasukawa, T., Suzuki, Y., and Okada-Hatakeyama, M. (2020). The Number of Transcription
1020 Factors at an Enhancer Determines Switch-like Gene Expression. *Cell Reports*, 31(9):107724.

1021 Mirny, L. a. (2010). Nucleosome-mediated cooperativity between transcription factors. *Proceedings
1022 of the National Academy of Sciences of the United States of America*, 107(52):22534–22539.

1023 Moon, K. J., Mochizuki, K., Zhou, M., Jeong, H. S., Brady, J. N., and Ozato, K. (2005). The
1024 bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA
1025 polymerase II-dependent transcription. *Molecular Cell*, 19(4):523–534.

1026 Narasimhan, K., Pillay, S., Huang, Y. H., Jayabal, S., Udayasuryan, B., Veerapandian, V., Ko-
1027 latkar, P., Cojocaru, V., Pervushin, K., and Jauch, R. (2015). DNA-mediated cooperativity
1028 facilitates the co-selection of cryptic enhancer sequences by SOX2 and PAX6 transcription fac-
1029 tors. *Nucleic Acids Research*, 43(3):1513–1528.

1030 Nie, Z., Guo, C., Das, S. K., Chow, C. C., Batchelor, E., Simons, S. S., and Levens, D. (2020).
1031 Dissecting transcriptional amplification by MYC. *eLife*, 9:1–32.

1032 O'Connor, L., Gilmour, J., and Bonifer, C. (2016). The role of the ubiquitously expressed trans-
1033 cription factor Sp1 in tissue-specific transcriptional regulation and in disease. *Yale Journal of
1034 Biology and Medicine*, 89(4):513–525.

1035 Ouyang, Z., Zhou, Q., and Wong, W. H. (2009). ChIP-Seq of transcription factors predicts absolute
1036 and differential gene expression in embryonic stem cells. *Proceedings of the National Academy
1037 of Sciences of the United States of America*, 106(51):21521–21526.

1038 Oven, I., Brdičková, N., Kohoutek, J., Vaupotič, T., Narat, M., and Peterlin, B. M. (2007). AIRE
1039 Recruits P-TEFb for Transcriptional Elongation of Target Genes in Medullary Thymic Epithelial
1040 Cells. *Molecular and Cellular Biology*, 27(24):8815–8823.

1041 Paakinaho, V., Presman, D. M., Ball, D. A., Johnson, T. A., Schiltz, R. L., Levitt, P., Mazza,
1042 D., Morisaki, T., Karpova, T. S., and Hager, G. L. (2017). Single-molecule analysis of steroid
1043 receptor and cofactor action in living cells. *Nature Communications*, 8(May):1–14.

1044 Pan, Y. and Nussinov, R. (2011). The Role of Response Elements Organization in Transcrip-
1045 tion Factor Selectivity: The IFN- β Enhanceosome Example. *PLoS Computational Biology*,
1046 7(6):e1002077.

1047 Park, J., Estrada, J., Johnson, G., Vincent, B. J., Ricci-Tam, C., Bragdon, M. D., Shulgina, Y.,
1048 Cha, A., Wunderlich, Z., Gunawardena, J., and DePace, A. H. (2019a). Dissecting the sharp
1049 response of a canonical developmental enhancer reveals multiple sources of cooperativity. *eLife*,
1050 8:e41266.

1051 Park, M., Patel, N., Keung, A. J., and Khalil, A. S. (2019b). Engineering Epigenetic Regulation
1052 Using Synthetic Read-Write Modules. *Cell*, 176(1-2):227–238.e20.

1053 Ptashne, M. (1988). How eukaryotic transcriptional activators work. *Nature*, 335(6192):683–689.

1054 Ptashne, M. (2005). Regulation of transcription: from lambda to eukaryotes. *Trends in Biochemical
1055 Sciences*, 30(6):275–279.

1056 Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., and
1057 Young, R. A. (2010). C-Myc regulates transcriptional pause release. *Cell*, 141(3):432–445.

1058 Raj, A., Peskin, C. S., Tranchina, D., Vargas, D. Y., and Tyagi, S. (2006). Stochastic mRNA
1059 synthesis in mammalian cells. *PLoS Biology*, 4(10):1707–1719.

1060 Ramos, A. I. and Barolo, S. (2013). Low-affinity transcription factor binding sites shape morphogen
1061 responses and enhancer evolution. *Philosophical Transactions of the Royal Society B: Biological
1062 Sciences*, 368(1632):20130018.

1063 Reiter, F., Wienerroither, S., and Stark, A. (2017). Combinatorial function of transcription factors
1064 and cofactors. *Current Opinion in Genetics and Development*, 43:73–81.

1065 Rybakova, K. N., Bruggeman, F. J., Tomaszewska, A., Moné, M. J., Carlberg, C., and Westerhoff,
1066 H. V. (2015). Multiplex Eukaryotic Transcription (In)activation: Timing, Bursting and Cycling
1067 of a Ratchet Clock Mechanism. *PLoS Computational Biology*, 11(4):1–24.

1068 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,
1069 Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K.,
1070 Tomancak, P., and Cardona, A. (2012). Fiji: An open-source platform for biological-image
1071 analysis. *Nature Methods*, 9(7):676–682.

1072 Scholes, C., DePace, A. H., and Sánchez, Á. (2017). Combinatorial Gene Regulation through
1073 Kinetic Control of the Transcription Cycle. *Cell Systems*, 4(1):97–108.e9.

1074 Schröder, S., Herker, E., Itzen, F., He, D., Thomas, S., Gilchrist, D. A., Kaehlcke, K., Cho, S.,
1075 Pollard, K. S., Capra, J. A., Schnölzer, M., Cole, P. A., Geyer, M., Bruneau, B. G., Adelman,
1076 K., and Ott, M. (2013). Acetylation of RNA Polymerase II Regulates Growth-Factor-Induced
1077 Gene Transcription in Mammalian Cells. *Molecular Cell*, 52(3):314–324.

1078 Sharova, L. V., Sharov, A. A., Nedorezov, T., Piao, Y., Shaik, N., and Ko, M. S. (2009). Database
1079 for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and
1080 differentiating mouse embryonic stem cells. *DNA Research*, 16(1):45–58.

1081 Singh, G., Mullany, S., Moorthy, S. D., Zhang, R., Mehdi, T., Tian, R., Duncan, A. G., Moses,
1082 A. M., and Mitchell, J. A. (2021). A flexible repertoire of transcription factor binding sites and
1083 a diversity threshold determines enhancer activity in embryonic stem cells. *Genome Research*,
1084 31(4):564–575.

1085 Smith, R. P., Taher, L., Patwardhan, R. P., Kim, M. J., Inoue, F., Shendure, J., Ovcharenko, I.,
1086 and Ahituv, N. (2013). Massively parallel decoding of mammalian regulatory sequences supports
1087 a flexible organizational model. *Nature Genetics*, 45(9):1021–1028.

1088 Spitz, F. and Furlong, E. E. M. (2012). Transcription factors: From enhancer binding to develop-
1089 mental control. *Nat. Rev. Genet.*, 13(9):613–626.

1090 Stampfel, G., Kazmar, T., Frank, O., Wienerroither, S., Reiter, F., and Stark, A. (2015). Tran-
1091 scriptional regulators form diverse groups with context-dependent regulatory functions. *Nature*,
1092 528(7580):147–151.

1093 Strasen, J., Sarma, U., Jentsch, M., Bohn, S., Sheng, C., Horbelt, D., Knaus, P., Legewie, S., and
1094 Loewer, A. (2018). Cell-specific responses to the cytokine TGF β are determined by variability
1095 in protein levels. *Molecular Systems Biology*, 14(1):1–17.

1096 Suter, D. M., Molina, N., Gatfield, D., Schneider, K., Schibler, U., and Naef, F. (2011). Mammalian
1097 Genes Are Transcribed with Widely Different Bursting Kinetics. *Science*, 332(6028):472–474.

1098 Vandel, J., Cassan, O., Lèbre, S., Lecellier, C. H., and Bréhélin, L. (2019). Probing transcription
1099 factor combinatorics in different promoter classes and in enhancers. *BMC Genomics*, 20(1):1–19.

1100 Vanhille, L., Griffon, A., Maqbool, M. A., Zacarias-Cabeza, J., Dao, L. T., Fernandez, N., Ballester,
1101 B., Andrau, J. C., and Spicuglia, S. (2015). High-throughput and quantitative assessment of
1102 enhancer activity in mammals by CapStarr-seq. *Nature Communications*, 6.

1103 Vashee, S., Willie, J., and Kodadek, T. (1998). Synergistic activation of transcription by physi-
1104 ologically unrelated transcription factors through cooperative DNA-Binding. *Biochemical and*
1105 *Biophysical Research Communications*, 247(2):530–535.

1106 Vasile, E., Hnisz, D., Klein, I. A., Young, R. A., Manteiga, J. C., Malik, S., Lee, T. I., Abraham,
1107 B. J., Schuijers, J., Cisse, I. I., Roeder, R. G., Dall’Agnese, A., Hannett, N. M., Day, D. S.,
1108 Boija, A., Coffey, E. L., Shrinivas, K., Li, C. H., Sabari, B. R., Sharp, P. A., Zamudio, A. V.,
1109 Chakraborty, A. K., and Guo, Y. E. (2018). Coactivator condensation at super-enhancers links
1110 phase separation and gene control. *Science*, 361(6400):eaar3958.

1111 Veitia, R. A. (2003). A sigmoidal transcriptional response: Cooperativity, synergy and dosage
1112 effects. *Biological Reviews of the Cambridge Philosophical Society*, 78(1):149–170.

1113 Wissink, E. M., Vihervaara, A., Tippens, N. D., and Lis, J. T. (2019). Nascent RNA analyses:
1114 tracking transcription and its regulation. *Nature Reviews Genetics*, 20(12):705–723.

1115 Wong, F. and Gunawardena, J. (2020). Gene Regulation in and out of Equilibrium. *Annual Review*
1116 *of Biophysics*, 49(1):199–226.


1117 Wong, V. C., Mathew, S., Ramji, R., Gaudet, S., and Miller-Jensen, K. (2019). Fold-Change
1118 Detection of NF- κ B at Target Genes with Different Transcript Outputs. *Biophysical Journal*,
1119 116(4):709–724.

1120 Wunderlich, Z. and Mirny, L. A. (2009). Different gene regulation strategies revealed by analysis
1121 of binding motifs. *Trends in Genetics*, 25(10):434–440.






1122 Yang, Z., Yik, J. H., Chen, R., He, N., Moon, K. J., Ozato, K., and Zhou, Q. (2005). Recruitment
1123 of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
1124 *Molecular Cell*, 19(4):535–545.

1125 **8 Supplementary Figures**

A) Basal rates between 1-10⁴, TF can modify a rate up to 1000x (0.001x)



B) Basal rates between 1-100, TF can modify a rate up to 100x (0.01x)



E)







Figure S1 Characterization of the model behavior in synergy space. (caption on next page)

(from previous page) A) Region of the synergy space spanned by the model when each TF acts uniquely on one of two steps, indicated in the title of each plot. The first plot is the same as in Figure 2B middle. Parameter values in the range between 1 and 10^4 . Parameters for the TFs at most 1000 times larger than the basal parameters for the clockwise rates (k_1, k_2, k_3) or 0.001 times smaller for k_4 . Fold change in m^* for each TF individually with respect to the basal condition with no TF bound between 1 and 10. B) Region of the synergy space from each of the 3 regulatory strategies in Figure 2B for more constrained parameters, representing weaker TFs: parameter values for the transitions over polymerase states in the range between 1 and 100 for the clockwise rates, 100-10000 for $k_{4,\emptyset}$; parameters for the TFs at most 100 times larger than the basal parameters for the clockwise rates (k_1, k_2, k_3) or 0.01 times smaller for k_4 . Fold change in m^* for each TF individually with respect to the basal condition with no TF bound between 1 and 10 (solid line) or 1 and 5 (dashed line). C) Random sample of points where both TFs act on any step, randomly sampled under the same constraints as in Figure 2B bottom (Methods, 6.4) and used for the distributions in Figure 2C and panels D and E of this Figure. D) Distribution of TF activity distances as a function of synergy class, binned by basal expression (expression in the absence of TFs, left), binding on-rate (middle), binding off-rate (right), for the points in panel C. E) Distribution of synergy values as a function of TF activity distance and binned by basal expression, binding on-rate or binding off-rate for the points with positive synergy in panel C (green points).






Figure S3 Experimental observation of synergy between a pair of TFs. (continued on next page)

(from previous page) A) Western Blot and corresponding quantification of the ZF-HSF1 protein as a function of ng of plasmid transfected (Methods, 6.11). B) Normalised GFP expression as measured by qPCR in response to SP1 synTF. The concentrations of plasmid used are scaled by the number of cells (Methods, 6.12) so that 125 and 250 ng are approximately equivalent to 10 and 20 ng in the flow cytometry experiments. Error bars denote SEM from technical replicates. C) Distribution of integrated Fluorescence intensity (FI) in arbitrary units (a.u.) as quantified from segmented nuclei for the control (gray, no synTF) and transfected samples using quantitative immunofluorescence targeting the HA-tag of synTFs. Data falling within the 5th-95th percentiles is shown for each dataset. Dashed line: background threshold defined as 2.5x median of control FI. SP1, c-Myc and SP1/c-Myc curves represent the 5th-95th percentile of values above threshold. (See Methods, 6.13 for details) D) Bar graph showing the percentage of positive transfected cells determined based on the background threshold shown in panel C. n is the number of quantified cells for each dataset above threshold. E) The combination of a synTF with the ZF alone only generates asymmetric synergy, where expression is between that of the ZF and that of the full TF. Error bars denote the ranges of the data. At least 3 biological replicates per combination, with 2-4 technical replicates each. F) Details of the fold change in expression for the conditions that generate the synergy plot in Figure 3C. Error bars denote the 95% confidence interval for the mean GFP fold change, obtained from bootstrapping the mean GFP fold change values from all the experiments for each condition. At least 3 biological replicates per combination, with 2-4 technical replicates each.




Figure S4 Synergy between a pair of TFs depends upon the binding and unbinding kinetics.
(continued on next page)

(from previous page) A) Example of the 12 possible changes in synergy when the unbinding rate (k_u) is modulated, for a common set of basal parameter values and different TFs. The biggest marker denotes highest affinity (lowest unbinding rate), and the smallest marker denotes lowest affinity (highest unbinding rate). The subplot titles indicate the behaviour as the unbinding rate is increased: both $S_{A,B}$ and $S_{B,A}$ decrease: nndd, ppdd, pndd. $S_{A,B}$ decreases but $S_{B,A}$ increases: nndi, pndi, ppdi. $S_{A,B}$ increases but $S_{B,A}$ decreases: nnid, npid, ppid. Both increase: nnii, npii, ppii. All lines share the same set of basal and binding/unbinding rates, but each corresponds to a given set of TF parameter values. Results have been selected out of all those found from a rejection-based sampling random search of parameter values. B) Example of the 12 possible changes in synergy when the binding rate (k_b) is modulated. As in A, each line corresponds to a pair of TF parameter values, but all of them share the same basal and binding and unbinding rates. The biggest marker denotes highest affinity (largest binding rate), and the smallest marker denotes lowest affinity (lowest binding rate). See Methods 6.5 for details.